https://trial.medpath.com/news/5c5528c30ce49b1f/vitestro-secures-70m-series-b-to-advance-autonomous-blood-collection-robot-for-us-market-entry 2026-03-12T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/b2d85e8fb75735de/johns-hopkins-develops-simplified-nanoparticles-for-in-body-car-t-cell-engineering 2026-03-11T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/a88e99f76e43ed48/curatis-partners-with-neupharma-for-corticorelin-development-in-japan-s-brain-edema-market 2026-03-11T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/e0f209b6c97a1c12/viagra-shows-promise-as-first-treatment-for-fatal-childhood-disease-leigh-syndrome 2026-03-11T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/5d01738863411664/uk-health-authorities-launch-joint-initiative-to-support-infectious-disease-trials-in-africa-and-asia 2026-03-11T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/22832af7cdfa8764/fda-introduces-device-access-restrictions-framework-for-flavored-e-cigarette-regulation 2026-03-11T17:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/6dde852610891067/biocorrx-secures-u-s-patent-for-biodegradable-naltrexone-implant-technology 2026-03-11T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/1d14167b1b0a296a/dna-origami-vaccine-platform-shows-promise-as-next-generation-alternative-to-mrna-vaccines 2026-03-11T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/16dcc807083a611f/spinogenix-completes-enrollment-in-phase-2-trial-of-tazbentetol-for-schizophrenia-treatment 2026-03-11T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/3e89bbfa406c4043/anacardio-secures-us-patent-for-heart-failure-drug-ac01-extending-protection-until-2042 2026-03-11T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/7572f30e4f1b4164/sino-biopharmaceutical-receives-nmpa-approval-for-pan-kras-inhibitor-tqb3205-clinical-trial 2026-03-11T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/6cfcfb8c9daa31c8/vima-therapeutics-raises-100m-to-advance-oral-therapy-for-movement-disorders 2026-03-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/8213743a97fc6756/fda-grants-breakthrough-device-designation-to-memed-s-ai-powered-infection-test 2026-03-11T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/967a224df6712eb1/arthex-biotech-receives-fda-fast-track-designation-for-atx-01-in-myotonic-dystrophy-type-1 2026-03-11T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/6c46e1fd9cfae059/verve-medical-initiates-u-s-pilot-trial-for-novel-renal-denervation-therapy-following-promising-tusk-results 2026-03-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/7d77b682c176d4b6/difgen-pharmaceuticals-secures-fda-approval-for-generic-mesalamine-extended-release-capsules 2026-03-11T17:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/86f0b783f9886ad0/commit-biologics-names-serial-biotech-entrepreneur-as-ceo-to-advance-complement-powered-immunotherapies 2026-03-11T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/2e783cff60050c8d/c2n-diagnostics-expands-alzheimer-s-blood-test-access-across-asia-through-strategic-partnerships 2026-03-11T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/abe385e5135a0d30/fda-clears-two-advanced-neurovascular-catheters-for-stroke-and-complex-brain-procedures 2026-03-11T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb03e549a8d752ab/pharmather-advances-microneedle-patch-platform-for-therapeutic-peptides-with-patchprint-manufacturing-system 2026-03-11T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/77d3536df92ad064/profound-medical-to-present-first-captain-trial-results-comparing-tulsa-procedure-to-robotic-prostatectomy 2026-03-11T09:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/47b874f38a25f3b2/sanara-medtech-s-celleraterx-surgical-powder-shows-3852-cost-savings-per-patient-in-spine-surgery-study 2026-03-11T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d50f08cbbf008f9/patrys-initiates-manufacturing-and-fda-engagement-for-injectable-delirium-treatment-rls-2201 2026-03-11T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/a507acd02a31fb98/acurastem-receives-target-als-grant-to-develop-syf2-targeted-therapeutics-for-tdp-43-dysfunction 2026-03-11T01:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/137641fb1f7872f9/heartbeam-partners-with-mount-sinai-to-develop-ai-powered-home-cardiac-monitoring-platform 2026-03-11T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/5e9af1da2422abc5/q32-bio-reports-positive-clinical-progress-for-bempikibart-in-alopecia-areata-with-36-week-data-expected-mid-2026 2026-03-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/088e4b5cd4b7e513/red-light-holland-acquires-filament-health-in-strategic-psychedelic-drug-development-merger 2026-03-11T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/f985846096e5f8d5/mindimmune-secures-5-million-addf-investment-to-advance-first-in-class-alzheimer-s-immunotherapy-miti-101 2026-03-11T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/78bf763ae46198c2/medicare-cbd-pilot-program-sparks-debate-over-fda-standards-for-cannabinoid-reimbursement 2026-03-11T01:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/d7fa8aeff9f7b716/stanford-study-identifies-statins-and-alpha-blockers-as-potential-life-extending-treatments-for-als-patients 2026-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c3d5f9ec1f5d104/neurothera-labs-acquires-majority-stake-in-cliniquantum-to-advance-quantum-powered-clinical-trials 2026-03-10T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/2acaf65f356dd066/first-in-human-photoswitch-therapy-shows-promise-for-advanced-retinitis-pigmentosa 2026-03-10T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/138f8c2fa0253e68/cerevance-reports-positive-phase-2-results-for-novel-parkinson-s-drug-solengepras-targeting-motor-fluctuations-and-sleep-symptoms 2026-03-10T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/89f730a5a9bacc85/alligator-bioscience-secures-uspto-patent-for-tetravalent-bispecific-antibody-platform 2026-03-10T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/c7057d3f34a3c02c/macrogenics-advances-adc-pipeline-with-three-clinical-programs-set-for-2026-data-readouts 2026-03-10T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/5aa565c09cac9298/nkgen-biotech-s-troculeucel-shows-dose-dependent-cognitive-benefits-in-phase-1-alzheimer-s-disease-trials 2026-03-10T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/5b0f331ec260a333/qlaris-bio-appoints-fred-guerard-as-ceo-as-qls-111-glaucoma-drug-enters-phase-3-development 2026-03-10T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/073c1230eddb393a/biovaxys-and-adiverna-partner-to-develop-world-s-first-ai-designed-mrna-vaccines-for-companion-animals 2026-03-10T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/bd877baceff9c0c2/piston-bio-secures-fda-alignment-for-first-in-class-cancer-related-apathy-treatment-pst-101 2026-03-10T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/1c5f70ab885d46c7/aptorum-group-and-diamir-biosciences-publish-breakthrough-study-on-blood-based-glioblastoma-detection-using-microrna-biomarkers 2026-03-10T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/24f741c200b14d96/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccine-portfolio 2026-03-10T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/8b1c88b5eef139b9/microbix-advances-manufacturing-modernization-for-kinlytic-urokinase-clot-dissolving-drug 2026-03-10T17:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/eabaead0bc1e5560/spark-biomedical-launches-phase-ii-luna-trial-testing-wearable-neurostimulation-for-heavy-menstrual-bleeding 2026-03-10T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/f8aa2294af5fe527/foundation-medicine-expands-combomatch-participation-with-blood-based-biomarker-testing 2026-03-10T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/1cdd54bf7cf9b85f/peptilogics-initiates-pivotal-trial-for-first-in-class-anti-biofilm-drug-plg0206-targeting-prosthetic-joint-infections 2026-03-10T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/1b435e489962a149/fda-approves-first-treatment-for-rare-cerebral-folate-transport-deficiency 2026-03-10T17:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/f4ca77b95e9af41e/kcas-bio-lyon-site-achieves-level-a-glp-compliance-renewal-strengthening-ind-enabling-study-support 2026-03-10T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/9a4426bdfbc57a2b/etvax-oral-vaccine-shows-promise-against-deadly-e-coli-infections-in-children 2026-03-10T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/7dad6a97c622f714/idorsia-expands-quviviq-access-to-gulf-states-through-pharmalink-partnership 2026-03-10T13:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/2cd691302b1b8dbd/c-further-launches-first-pediatric-cancer-programs-with-40m-budget-partners-with-mink-therapeutics 2026-03-10T13:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/25485022f0b06075/daily-multivitamin-supplementation-slows-biological-aging-by-up-to-5-months-in-randomized-trial 2026-03-10T13:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/72f75f684bd3e07a/korro-bio-advances-rna-editing-platform-with-krro-121-nomination-and-85-million-financing 2026-03-10T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/d9c1ac83faf327e3/lipum-secures-eur8-million-eu-grant-for-phase-2-rheumatoid-arthritis-trial-of-novel-bssl-targeting-antibody 2026-03-10T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/36ed37af628a415e/chinese-scientists-develop-face-platform-to-overcome-car-t-therapy-resistance-in-leukemia 2026-03-10T13:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/e6fa8b6e294c421f/kainova-therapeutics-reports-positive-phase-i-results-for-oral-ep4-receptor-antagonist-dt-9081-in-advanced-solid-tumors 2026-03-10T13:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/75ede470f72af9db/nuformix-secures-fda-orphan-drug-designation-for-inhaled-ipf-therapy-nxp002 2026-03-10T13:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/e6964550a333380e/biontech-co-founders-sahin-and-tureci-to-establish-new-mrna-company-by-2026 2026-03-10T13:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/ef50412bb98e2b16/fda-eliminates-two-trial-requirement-for-drug-approvals-shifting-to-single-trial-default 2026-03-10T13:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/2ac1cb40c239cc83/cannabis-compounds-show-promise-for-treating-liver-disease-affecting-one-third-of-adults 2026-03-10T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/a4f4e3c8945325a0/sandoz-restructures-operations-and-expands-biosimilar-pipeline-through-samsung-bioepis-partnership 2026-03-10T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/3b552d7d03129009/ards-clinical-pipeline-expands-with-50-companies-developing-novel-therapies 2026-03-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/50faf4fc3a2242c2/kaist-researchers-develop-next-generation-mrna-platform-to-overcome-efficacy-loss-in-elderly-and-obese-patients 2026-03-10T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/6ea6e36f67743ca0/ibio-s-ibio-610-shows-fat-selective-weight-loss-in-non-human-primate-study 2026-03-10T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/92d12efa6a9a8340/dobermann-trials-test-early-interventions-to-prevent-cardiogenic-shock-in-high-risk-ami-patients 2026-03-10T01:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/6a027a7f71fcd016/intravascular-imaging-shows-sustained-clinical-benefits-at-5-years-in-complex-pci-procedures 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9520c34f68a72ce4/revive-therapeutics-expands-bucillamine-patent-portfolio-with-north-american-filings-for-chemical-warfare-agent-treatment 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d784a38b5944d98a/care-ventures-group-invests-in-ren-health-to-build-ai-powered-women-s-wellness-platform 2026-03-09T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/6e6462d06501a850/csl-invests-1-5-billion-to-expand-illinois-plasma-therapy-manufacturing-with-advanced-horizon-2-technology 2026-03-09T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/33389d9d228b9251/ge-healthcare-receives-fda-510-k-clearance-for-cloud-native-diagnostic-viewer 2026-03-09T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/c89a3a84ac6f65bb/brogidirsen-shows-sustained-motor-function-preservation-in-4-5-year-duchenne-muscular-dystrophy-trial 2026-03-09T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/dbc358dbfe69d1a9/health-canada-approves-koselugo-for-adult-neurofibromatosis-type-1-patients-with-plexiform-neurofibromas 2026-03-09T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/7915174a94cc1573/emalex-biosciences-initiates-expanded-access-program-for-novel-tourette-syndrome-therapy-ecopipam 2026-03-09T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/f0b68ea4895a3427/verily-and-samsung-partner-to-integrate-galaxy-watch-8-data-into-clinical-research-platform 2026-03-09T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/5d1a0d3ee0339d58/medidata-and-menarini-group-expand-ai-powered-partnership-to-accelerate-oncology-clinical-trials 2026-03-09T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/581d82f06c0ee869/crestone-s-crs3123-shows-superior-efficacy-in-phase-2-trial-for-c-difficile-infections 2026-03-09T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/8ece0602aa36a919/junshi-biosciences-achieves-regulatory-milestone-with-first-domestic-subcutaneous-anti-pd-1-antibody-application-in-china 2026-03-09T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/659e4e684bbafdaa/novelmed-s-ruxoprubart-achieves-100-transfusion-independence-in-pnh-phase-ii-trial-gains-regulatory-clearance-for-subcutaneous-dosing 2026-03-09T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/b53c7ef5ce006ea4/lonza-and-genetix-extend-manufacturing-partnership-for-zynteglo-gene-therapy-amid-rising-patient-demand 2026-03-09T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/a0cdb16bcbdb3d10/fda-clears-first-dental-dedicated-mri-system-following-successful-clinical-trial 2026-03-09T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/3cff1762e2776b4f/tme-pharma-secures-12-month-loan-extension-extends-cash-runway-to-q2-2027 2026-03-09T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/a2b89dad2cc7773c/agilent-acquires-biocare-medical-for-950-million-to-expand-cancer-diagnostics-portfolio 2026-03-09T13:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/c82918a1278da05b/atamyo-therapeutics-reports-promising-early-results-for-ata-200-gene-therapy-in-rare-muscular-dystrophy 2026-03-09T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/54d611eded960954/lundbeck-completes-early-patient-enrollment-in-phase-3-trial-for-rare-neurodegenerative-disease-msa 2026-03-09T13:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/6448516544651f47/bioduro-and-cenra-form-strategic-joint-venture-to-strengthen-global-api-manufacturing-network 2026-03-09T13:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/8c6613e09c056291/kyron-bio-partners-with-servier-to-advance-precision-glycoengineering-for-next-generation-antibody-therapeutics 2026-03-09T13:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/bb7387b3d2d0471a/harbour-biomed-and-kelun-biotech-receive-nmpa-approval-for-novel-bispecific-antibody-targeting-atopic-dermatitis 2026-03-09T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/0b41c51b4e752bd7/heidelberg-pharma-secures-45-million-through-modified-licensing-agreement-with-healthcare-royalty-and-soleus-capital 2026-03-09T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/45bcc3a092800869/t-knife-therapeutics-receives-european-authorization-for-first-in-human-trial-of-crispr-edited-t-cell-therapy-tk-6302 2026-03-09T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/526d9132dc7b8fa9/lifevac-becomes-first-fda-authorized-suction-anti-choking-device-for-emergency-airway-clearance 2026-03-09T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/5e9ca3e38243b959/dianthus-therapeutics-announces-interim-results-from-phase-3-captivate-trial-of-claseprubart-for-cidp 2026-03-09T01:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/920497bfcec6cb30/nsw-government-expands-funding-for-cancer-clinical-trials-alliance-improving-patient-access-across-australia 2026-03-09T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/650957cc2231ea01/claritas-neurocloudtm-receives-anvisa-approval-for-ai-powered-brain-imaging-analysis-in-brazil 2026-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/251d19546912432f/sk-biopharmaceuticals-acquires-full-control-of-u-s-r-d-unit-with-36-million-investment-to-advance-cancer-pipeline 2026-03-08T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/3cd365c720724540/amgen-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-in-advanced-melanoma 2026-03-08T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/fa862ec471ccdb25/contineum-therapeutics-advances-pipe-791-phase-2-trial-for-idiopathic-pulmonary-fibrosis-with-differentiated-lpa1-receptor-targeting 2026-03-08T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/5d59990e3f1df95d/self-amplifying-rna-therapy-shows-promise-for-heart-attack-recovery-in-preclinical-studies 2026-03-08T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/1e9e61aa38c47569/cathworks-ffrangio-demonstrates-non-inferiority-to-invasive-pressure-wire-assessment-in-landmark-all-rise-trial 2026-03-08T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/2f5eecbde8d80b81/ataibeckley-explores-2-billion-deal-for-psychedelic-depression-drug-as-deutsche-bank-sees-major-market-potential 2026-03-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/75665353aaaaa1b2/two-major-oncology-companies-terminate-early-stage-solid-tumor-trials 2026-03-07T21:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/6cba428c0edf5d44/novel-therapeutic-strategies-target-chemoresistance-mechanisms-in-small-cell-lung-cancer 2026-03-07T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/d2063d9ab62c51b6/ono-pharmaceutical-expands-ai-driven-drug-discovery-into-neurology-and-immunology-through-strategic-partnerships 2026-03-07T10:45:13+00:00 hourly 0.9 https://trial.medpath.com/news/d9d2b89be968ba90/amarin-faces-revenue-decline-as-vascepa-confronts-generic-competition-in-us-market 2026-03-07T10:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/969f87e4f86a04a4/u-s-patient-with-advanced-nsclc-achieves-disease-stabilization-with-ivonescimab-in-china 2026-03-07T10:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/d5572f35d2f99370/heidelberg-pharma-advances-novel-atac-technology-platform-with-multiple-cancer-candidates-in-clinical-development 2026-03-07T05:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/c7ad456d633b3abe/inmed-pharmaceuticals-winds-down-baymedica-operations-to-focus-on-cb1-cb2-receptor-drug-pipeline 2026-03-07T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/048665765ed64e89/uk-government-establishes-world-first-regulatory-framework-for-space-manufactured-medicines 2026-03-07T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/c79a819052c79caf/hamlet-biopharma-signs-letter-of-intent-for-alpha-1h-bladder-cancer-therapy-partnership 2026-03-07T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/f83296c9b41e19fa/d-d-pharmatech-and-first-bio-secure-european-patent-for-novel-brain-disease-drug-nly02 2026-03-07T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/bed1de0374f738b3/hypofractionated-radiotherapy-shows-promise-for-breast-cancer-treatment-with-reduced-treatment-time 2026-03-07T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/fb92bc89079464b3/mindwalk-unveils-b-cell-llama-platform-for-next-generation-nanobody-discovery 2026-03-07T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/8d80f3e786c440c4/fda-approves-lantheus-pylarify-truvu-for-enhanced-prostate-cancer-imaging 2026-03-07T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/1e17525d2c09f058/aisa-pharma-s-aisa-021-shows-promise-in-phase-2-trial-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-03-06T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/9c86e77a4750aebe/ketone-body-b-hydroxybutyrate-enhances-car-t-cell-therapy-efficacy-in-preclinical-studies-human-trials-underway 2026-03-06T21:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/3af5a06b53616155/cancer-clinical-trials-systematically-underreport-thromboembolic-risks-researchers-warn 2026-03-06T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/26eba35461614f9b/sanofi-pfizer-ceacam5-adc-trial-halted-in-europe-as-merck-kgaa-advances-competing-asset-to-phase-3 2026-03-06T21:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/222515dfb4e47d32/stpharm-initiates-nipah-virus-mrna-vaccine-production-for-korean-pandemic-preparedness-initiative 2026-03-06T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/71f6fca424b022aa/servier-acquires-day-one-biopharmaceuticals-for-2-5-billion-to-strengthen-rare-oncology-portfolio 2026-03-06T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/9d85f77fe8d6203e/diamedica-receives-health-canada-approval-for-phase-ii-preeclampsia-trial-of-dm199 2026-03-06T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/43c418841797e942/rowan-university-develops-first-robotic-system-for-minimally-invasive-long-bone-fracture-surgery 2026-03-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/c879e05e8269ba15/ema-issues-first-eu-guidance-for-clinical-trials-during-public-health-emergencies 2026-03-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/b13ba1a7fa40d953/sanofi-executive-calls-for-fundamental-shift-in-clinical-trial-supply-models-amid-rising-market-pressures 2026-03-06T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/174127c12e2623d6/vietnam-launches-clinical-trials-for-xafty-world-s-first-oral-antiviral-drug-for-dengue-fever-treatment 2026-03-06T13:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/3202f2a019434cce/cancer-patients-and-families-campaign-for-nhs-approval-of-zanidatamab-for-bile-duct-cancer 2026-03-06T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/3611b1d648aab426/exthera-medical-executive-pleads-guilty-to-concealing-patient-deaths-from-fda-in-blood-filtration-device-case 2026-03-06T05:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/db610883b35e744b/cdt-equity-leverages-ai-platform-to-identify-rare-disease-drug-opportunities-across-multiple-therapeutic-areas 2026-03-06T01:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/3a2bda9bc36c598a/hopewell-therapeutics-sublicenses-tissue-targeting-lipid-nanoparticles-to-foxcroft-for-novel-cancer-vaccine-development 2026-03-06T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/29e9adaa78f69819/lineage-cell-therapeutics-reports-positive-36-month-opregen-data-and-manufacturing-milestones-in-2025 2026-03-06T01:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/d25da061dc7f8989/merck-kgaa-deepens-china-investment-with-eur170-million-manufacturing-expansion-and-drug-development-partnership 2026-03-06T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/80d9ee032d25ae7e/inimmune-appoints-new-chief-medical-officer-and-head-of-financial-strategy-ahead-of-phase-2-allergic-rhinitis-data 2026-03-06T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/a626de9c4f0c43f6/caredx-launches-vantx-ai-platform-for-transplant-data-analytics-and-announces-170m-lab-products-divestiture 2026-03-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/7ec8b2d513b9c240/incyte-advances-kras-g12d-inhibitor-to-phase-3-despite-fatal-pneumonitis-and-european-clinical-hold 2026-03-06T01:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/bf93ee0430a503cb/car-t-cell-therapy-achieves-remission-in-15-year-blood-cancer-patient-at-corewell-health 2026-03-06T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/e6354b7d54d1b90e/bd-receives-ce-mark-approval-for-revello-vascular-covered-stent-to-treat-peripheral-artery-disease 2026-03-06T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/31414fa89eb303a5/kestrel-therapeutics-receives-fda-clearance-for-pan-kras-inhibitor-kst-6051-phase-1-trial 2026-03-05T21:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/34b27ac167761a2d/quanta-therapeutics-direct-kras-inhibitors-show-promise-against-resistance-to-pan-ras-tri-complex-therapies 2026-03-05T21:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/1956397bf5dfbd19/medincell-raises-capital-to-advance-long-acting-injectable-platform-and-expand-partnerships 2026-03-05T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/ce0a363a2dbc75a3/tangram-therapeutics-initiates-first-in-human-trial-of-tgm-312-for-mash-treatment 2026-03-05T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/7b7861610b8039de/fak-inhibition-unlocks-immune-response-against-treatment-resistant-ovarian-cancer 2026-03-05T21:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/e00ec4a6917d2f7f/stem-cells-from-baby-teeth-show-promise-for-treating-cerebral-palsy-in-clinical-and-preclinical-studies 2026-03-05T21:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/e75c8bdaafcfa59e/cognito-therapeutics-secures-105-million-series-c-to-advance-at-home-alzheimer-s-device-toward-2027-launch 2026-03-05T21:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/de65df84fc20e60a/lifecore-biomedical-expands-partnership-with-indomo-to-advance-at-home-acne-treatment-device 2026-03-05T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/39e665382ec71666/bioxcel-s-bxcl501-shows-promise-in-phase-2-trial-for-opioid-withdrawal-treatment 2026-03-05T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/fd3f8938775051d2/liberate-bio-secures-myeloid-optimized-car-design-licenses-to-advance-in-vivo-car-m-programs 2026-03-05T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/0e66ef9f4e39dc2b/therna-partners-with-charles-river-to-develop-ai-designed-single-patient-rna-therapeutics-for-ultra-rare-diseases 2026-03-05T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/f665dbabc720427c/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment 2026-03-05T17:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/38c6c052d8af1326/immunis-secures-exclusive-license-for-novel-parkinson-s-dyskinesia-treatment-kora 2026-03-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/412b9220f9c9f5ea/cspc-pharmaceutical-achieves-clinical-milestone-with-sirolimus-injection-for-rare-cancer-treatment 2026-03-05T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/b2a3e3b3ec5a97e9/shilpa-medicare-receives-nclt-approval-for-subsidiary-merger-to-streamline-operations 2026-03-05T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/3ad9732d117b22f1/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies 2026-03-05T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/5979cfd62dab5a00/chinese-study-shows-neoadjuvant-therapy-nearly-doubles-disease-free-survival-in-intrahepatic-cholangiocarcinoma 2026-03-05T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/912cec8339d3aafb/science-corp-raises-230m-series-c-to-advance-prima-brain-computer-interface-for-vision-restoration 2026-03-05T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/02fe8da94bb70727/seqster-launches-1-click-datalake-platform-to-transform-clinical-trial-design-and-recruitment 2026-03-05T17:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/457d2718032ccbab/fda-grants-breakthrough-device-designation-to-cognita-s-ai-powered-chest-x-ray-interpretation-system 2026-03-05T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/9d4519e36044ba8a/new-zealand-proposes-public-funding-for-letermovir-to-prevent-life-threatening-cmv-infections-after-stem-cell-transplants 2026-03-05T05:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/b01daeb5a60bbc89/brazilian-single-dose-dengue-vaccine-shows-80-5-efficacy-against-hospitalization-in-five-year-phase-3-trial 2026-03-05T05:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/9e74875f932f68a9/gossamer-bio-s-seralutinib-fails-phase-3-prosera-trial-due-to-stringent-statistical-threshold 2026-03-05T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/34c8dfe9603b3c86/medidata-and-crio-partnership-delivers-near-perfect-data-accuracy-across-2500-global-clinical-trial-sites 2026-03-05T05:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/828f631969d88202/cytisinicline-shows-promise-for-smoking-cessation-even-in-treatment-resistant-patients-phase-3-data-reveals 2026-03-05T01:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/dbdf595aa0375ae9/experimental-drug-zorevunersen-shows-up-to-91-seizure-reduction-in-children-with-dravet-syndrome 2026-03-05T01:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/664d05e02e736518/cordenpharma-colorado-expands-peptide-development-capabilities-with-64000-square-foot-leed-gold-facility-at-flatiron-park 2026-03-04T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/d193bf3fff978d06/immunoscape-s-novel-seed-and-boost-platform-achieves-100-survival-in-ovarian-cancer-model-advances-to-clinical-trial 2026-03-04T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/2467fab7c187df2f/sino-biological-launches-antigens-for-2026-2027-influenza-vaccine-strains-following-who-recommendations 2026-03-04T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/0ca32ec7e20b182a/nervgen-pharma-strengthens-leadership-team-with-key-regulatory-and-patient-advocacy-appointments 2026-03-04T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/7525d873af69e071/cordis-launches-selution-slr-drug-eluting-balloon-in-japan-with-strong-three-year-clinical-data 2026-03-04T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/ffa2fd9c98b40d91/bryet-files-ind-application-for-ml-016-oncology-therapy-targeting-advanced-solid-tumors 2026-03-04T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/955a6c76abc342c5/researchers-identify-novel-therapeutic-strategy-for-rett-syndrome-through-alternative-splicing-modulation 2026-03-04T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/c51fadcb04f59389/stryker-launches-mako-rps-handheld-robotic-system-for-total-knee-replacement-surgery 2026-03-04T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/68246abef65b7e04/an2-therapeutics-expands-epetraborole-development-into-phase-2-trial-for-polycythemia-vera 2026-03-04T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/e80c3ba4107a23e6/biotech-successfully-transitions-live-phase-i-oncology-trial-from-manual-processes-to-automated-rtsm-system 2026-03-04T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/c892a615f6e9685b/alithea-genomics-secures-8-9m-to-scale-rna-sequencing-technology-for-drug-discovery 2026-03-04T17:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/16b4faff25ad82ac/vericel-secures-fda-approval-for-advanced-cell-therapy-manufacturing-facility-to-expand-maci-production 2026-03-04T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/37aa919c0bf3d8f2/inovio-and-akeso-partner-to-test-novel-dna-bispecific-antibody-combination-for-glioblastoma-treatment 2026-03-04T17:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/0519c2dd0f0c314d/fda-approves-first-ai-enabled-imaging-device-for-breast-cancer-surgery-margin-assessment 2026-03-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/9fd1a8e8f569c939/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis-offering-hope-for-rare-voice-threatening-disease 2026-03-04T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/9346f27971071e23/novabridge-s-vis-101-shows-promising-phase-2a-results-in-wet-amd-with-potential-best-in-class-durability 2026-03-04T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/97fa26a714defe03/ucb-secures-1-1b-license-for-antengene-s-masked-t-cell-engager-atg-201-in-autoimmune-disease-push 2026-03-04T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/89a5b5231e70eb4b/theolytics-secures-eur8-million-eu-grant-to-advance-novel-oncolytic-immunotherapy-for-platinum-resistant-ovarian-cancer 2026-03-04T13:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/a15c3b01bb8b09f6/roche-commits-520-million-investment-to-establish-south-korea-as-asian-clinical-trial-hub 2026-03-04T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/aa6f9949a4e3da63/genevant-sciences-and-arbutus-biopharma-secure-2-25-billion-settlement-with-moderna-over-covid-19-vaccine-patent-infringement 2026-03-04T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/3ba65b8f91143dce/teva-secures-400-million-from-blackstone-to-advance-tl1a-targeting-antibody-for-ibd-treatment 2026-03-04T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/be33adb165537bfe/fda-approves-first-generic-fluticasone-propionate-inhaler-with-180-day-market-exclusivity 2026-03-04T01:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/671d5f4125238103/fda-grants-de-novo-clearance-to-ai-powered-ultrasound-technology-for-predicting-delivery-dates 2026-03-04T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/608196ef332ceb02/cour-pharma-s-cnp-104-shows-sustained-liver-function-improvements-in-primary-biliary-cholangitis-one-year-study 2026-03-03T21:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/a3e70b648e6e4e1d/fda-accepts-pbpk-modeling-to-replace-ten-clinical-trials-for-cml-drug-asciminib 2026-03-03T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/4b0cef563883781d/sihuan-pharmaceutical-s-bireociclib-receives-nmpa-approval-for-first-line-hr-her2-advanced-breast-cancer-treatment 2026-03-03T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/4b44fca14fc9da68/implanet-secures-fda-clearance-for-3d-printed-swingo-cervical-spine-cage 2026-03-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/04ca1ebdcc3c74da/insilico-medicine-and-liquid-ai-launch-lightweight-ai-model-for-on-premise-drug-discovery 2026-03-03T21:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/e9c9a22e2ffd249b/yank-technologies-secures-2m-u-s-army-contract-for-wireless-charging-technology-development 2026-03-03T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/82325229753f6c38/reprocell-launches-fda-compliant-gmp-manufacturing-platform-for-clinical-ipscs 2026-03-03T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/ee90fd16318cd364/isct-and-jsrm-launch-five-year-strategic-partnership-to-advance-ipsc-based-therapies-globally 2026-03-03T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/88c81ececfb860e0/mount-sinai-and-king-saud-university-launch-three-year-precision-medicine-initiative-for-familial-ibd 2026-03-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/6ebf7cc7dfc17ce5/antiverse-raises-9-3m-series-a-to-develop-ai-designed-antibodies-for-challenging-disease-targets 2026-03-03T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/2d99c6a618d18794/cirrus-therapeutics-expands-to-singapore-unveils-novel-rpe-cell-therapy-for-geographic-atrophy 2026-03-03T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/05fe33a82f0adb2c/aspen-pharmacare-targets-canadian-market-entry-with-generic-ozempic-by-q3-2024 2026-03-03T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/4de6e68b6dcc8f3c/antiverse-secures-9-3m-series-a-to-advance-ai-powered-antibody-discovery-platform 2026-03-03T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/49ee587ecc9438e3/quell-therapeutics-launches-phase-1-2-trial-of-novel-car-treg-therapy-for-autoimmune-diseases 2026-03-03T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/c63e03914c026149/hepion-pharmaceuticals-in-licenses-novel-ctrna-biomarker-assay-for-early-hepatocellular-carcinoma-detection 2026-03-03T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/d3a415ec2d50b311/northsea-therapeutics-secures-orphan-drug-designations-for-orziloben-in-rare-liver-disease 2026-03-03T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/f83674894df1e92e/adela-s-blood-based-test-shows-strong-predictive-power-for-immunotherapy-response-in-advanced-solid-tumors 2026-03-03T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/d056a3fd76dba240/splisense-receives-ema-e-prime-designation-for-spl84-antisense-therapy-in-cystic-fibrosis 2026-03-03T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/d00858ae8f5a4294/fda-approves-juxtapid-for-pediatric-patients-with-homozygous-familial-hypercholesterolemia 2026-03-03T17:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/712be792e55b9cc8/syntis-bio-doses-first-patient-in-phase-1-1b-trial-of-novel-oral-obesity-treatment-synt-101 2026-03-03T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/560edb7953fc9ddc/progeria-research-foundation-partners-with-forge-biologics-to-advance-crispr-gene-therapy-for-rare-aging-disease 2026-03-03T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/5b1f83172099f6d2/theravance-biopharma-s-phase-3-cypress-study-fails-primary-endpoint-company-winds-down-ampreloxetine-program 2026-03-03T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/3c2cc6c92d86a356/fda-clears-harrow-s-phase-3-trial-for-triesence-in-cataract-surgery-patients 2026-03-03T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/a6f7fa2e10699001/growth-hormone-receptor-emerges-as-promising-target-for-therapy-resistant-lung-cancer 2026-03-03T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/e5c3bb81c11bd950/sanaregen-vision-therapeutics-receives-fda-clearance-for-phase-i-ii-trial-of-cell-therapy-for-familial-drusen 2026-03-03T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/7134eb540afa4a9d/ataibeckley-advances-bpl-003-to-phase-3-trials-for-treatment-resistant-depression-following-fda-approval 2026-03-03T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/c6218cd427d1bb12/secarna-pharmaceuticals-expands-ai-powered-oligonucleotide-partnership-with-curie-bio 2026-03-03T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/4b4d70a9cec51a25/senhwa-biosciences-partners-with-ai-biotech-celltype-to-transform-cx-4945-into-next-generation-immunotherapy-platform 2026-03-03T13:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/4ea6a920d03bd29f/hua-medicine-s-first-in-class-diabetes-drug-dorzagliatin-gains-hong-kong-approval-marking-international-expansion-milestone 2026-03-03T13:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/b41204d170f30e87/snipr-s-crispr-armed-phage-therapy-snipr001-demonstrates-safety-in-first-human-trial 2026-03-03T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/fac8c94dc4e7fd3c/congruence-therapeutics-and-ono-pharmaceutical-expand-partnership-to-target-neurology-and-immunology-programs 2026-03-03T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/4595c5085b16dd16/two-major-cannabinoid-companies-achieve-european-cep-certification-for-pharmaceutical-grade-cbd 2026-03-02T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6e481a32d259c93/argo-biopharma-strengthens-leadership-with-appointment-of-dr-gena-wang-as-cfo-and-chief-strategy-officer 2026-03-02T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/4f5097371a0eb826/low-dose-lithium-shows-promise-in-slowing-verbal-memory-decline-in-mild-cognitive-impairment 2026-03-02T21:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/d4667a4fa56b2aa8/monopar-therapeutics-strengthens-leadership-team-ahead-of-alxn1840-nda-submission-for-wilson-disease 2026-03-02T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/367fb7e4436eca53/imviva-s-allogeneic-car-t-therapy-cta313-achieves-100-response-rate-in-systemic-lupus-erythematosus-trial 2026-03-02T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/c2f0b2a36e0833a2/bioatla-initiates-strategic-review-process-amid-major-restructuring-and-70-workforce-reduction 2026-03-02T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/86529b9840f69f80/xellsmart-secures-fourth-consecutive-fda-and-nmpa-approval-for-ipsc-cell-therapy-targeting-rare-neurodegenerative-disease-msa-p 2026-03-02T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/50ce8a8bf30d35c5/early-phase-clinical-trial-outsourcing-market-projected-to-reach-14-8-billion-by-2030-driven-by-personalized-medicine-growth 2026-03-02T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/978e9ac93a6ebb32/revir-therapeutics-initiates-phase-1-trial-of-rtx-117-for-rare-neurological-diseases 2026-03-02T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/20fee8ebfe2f4449/gyre-therapeutics-acquires-cullgen-for-300m-to-expand-protein-degradation-platform 2026-03-02T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/83489c95433b4bc9/rallybio-and-candid-therapeutics-announce-505-million-merger-to-advance-t-cell-engager-pipeline-for-autoimmune-diseases 2026-03-02T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/5483276a89f834ce/longbio-s-lp-003-demonstrates-superior-efficacy-over-xolair-in-phase-ii-chronic-urticaria-trial 2026-03-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/1f3fb15e0a379d66/abbvie-s-skyrizi-demonstrates-superior-efficacy-in-phase-3-crohn-s-disease-trial-with-subcutaneous-induction 2026-03-02T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/47bf706af9d64ad5/bd-receives-fda-clearance-for-first-1000ml-antimicrobial-irrigation-system-for-powered-surgical-lavage 2026-03-02T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/c5f70f7d51efc99d/lantheus-receives-fda-tentative-approval-for-first-generic-version-of-lutathera-for-neuroendocrine-tumors 2026-03-02T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/ed5dd556a6afa546/talphera-reaches-50-enrollment-in-nafamostat-crrt-trial-targets-2026-fda-filing 2026-03-02T17:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/a5a9db734daf69b8/elutia-appoints-pete-ligotti-as-cco-to-lead-nxt-41x-commercial-launch-in-1-5b-breast-reconstruction-market 2026-03-02T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/e357ac29f68ddc42/avenacy-launches-generic-diphenhydramine-injectable-marking-26th-product-since-2023-inception 2026-03-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/9179333d64504d5a/alaunos-therapeutics-reports-promising-preclinical-data-for-non-hormonal-obesity-drug-aln1003 2026-03-02T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0ffdb9a1da1908f/united-therapeutics-ralinepag-achieves-55-risk-reduction-in-pivotal-pah-trial-paving-way-for-fda-submission 2026-03-02T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/67461ca259204baa/otsuka-s-paradise-ultrasound-renal-denervation-system-gains-insurance-coverage-in-japan-for-resistant-hypertension 2026-03-02T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/ec75938e6d7f4ac2/jingfang-medicine-s-gfh375-receives-china-s-first-breakthrough-therapy-designation-for-kras-g12d-mutated-nsclc 2026-03-02T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/7044a803f7c1506f/roquefort-therapeutics-acquires-tacc3-inhibitor-ao-252-in-ps31-9m-deal-rebrands-as-coiled-therapeutics 2026-03-02T05:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/443645c935cd5f45/xenon-pharmaceuticals-epilepsy-drug-azetukalner-achieves-record-breaking-trial-results-paving-way-for-fda-approval 2026-03-02T01:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/30a22494a05decad/university-of-chicago-develops-targeted-mrna-nanoparticle-system-to-prevent-type-1-diabetes-progression 2026-03-01T21:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/aff45d42097aa4aa/himalaya-trial-5-year-data-shows-durable-survival-benefit-for-stride-regimen-in-advanced-hepatocellular-carcinoma 2026-03-01T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/abb11f032ddbe1bd/ssy-group-secures-first-in-china-approval-for-fat-soluble-vitamin-injection-expands-medical-device-portfolio 2026-03-01T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/783ac8288df6cd27/caplin-steriles-secures-fda-approval-for-generic-desmopressin-injection-in-26-million-market 2026-03-01T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/fe3da1c67f9a70a4/n4-pharma-pivots-to-rna-therapeutics-with-new-ceo-and-thalia-therapeutics-rebrand 2026-03-01T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/7239bcacb5422fdb/hiv-cure-trial-shows-54-of-placebo-recipients-achieve-prolonged-viral-remission-after-receiving-experimental-therapy 2026-03-01T16:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/94d82b8f4ec62cbb/innocan-pharma-receives-third-consecutive-fda-fee-waiver-for-cannabidiol-based-pain-treatment-in-dogs 2026-03-01T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ec4247b98a6d574/biocytogen-reaches-clinical-milestone-as-first-patient-dosed-in-ideaya-s-b7h3-ptk7-bispecific-adc-phase-1-trial 2026-03-01T16:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/9c9cd5f1b6c24e55/fda-approves-biomarin-s-palynziq-for-adolescents-with-pku-expanding-treatment-access-to-ages-12-and-older 2026-03-01T16:42:10+00:00 hourly 0.9 https://trial.medpath.com/news/271243da9114850c/fda-approves-novo-nordisk-s-sogroya-for-three-additional-pediatric-growth-disorders 2026-02-28T01:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/1c61dbee0deaac83/one-third-of-rheumatologists-view-bristol-myers-squibb-s-sotyktu-as-substantial-advance-for-psoriatic-arthritis-ahead-of-march-6-fda-decision 2026-02-27T21:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/bd0a182d42d3d77b/gallant-partners-with-mwi-animal-health-to-establish-first-ultra-low-temperature-cold-chain-for-veterinary-stem-cell-therapy 2026-02-27T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/ddac6f7a74d99b32/flare-therapeutics-reports-promising-phase-1a-results-for-first-in-class-pparg-inhibitor-fx-909-in-advanced-urothelial-cancer 2026-02-27T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/4d8f5bc63851516a/neonc-technologies-to-present-phase-1-neo212-01-dose-escalation-results-for-cns-cancer-treatment 2026-02-27T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/ed0b857ba44c8e30/blue-jet-healthcare-announces-2300-crore-pharmaceutical-manufacturing-facility-in-andhra-pradesh 2026-02-27T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/ba5bbb995dc946ee/ema-accepts-marketing-authorization-application-for-cevira-first-in-class-photodynamic-therapy-for-cervical-lesions 2026-02-27T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/d4256e95f0c998dc/ema-approves-first-single-dose-oral-treatment-for-african-sleeping-sickness 2026-02-27T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/7c84fd8a66c84bd7/european-regulators-diverge-on-alzheimer-s-drug-approvals-as-italy-halts-reimbursement 2026-02-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f77117f24592e081/opko-health-advances-modex-pipeline-with-five-clinical-programs-and-merck-ebv-vaccine-partnership 2026-02-27T06:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/309c455dcc54c0d6/synthekine-partners-with-merck-to-evaluate-stk-012-combination-therapy-in-phase-2-nsclc-trial 2026-02-27T05:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/fe41e6329549ed8a/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-advance-exoedit-gene-editing-platform-for-neurological-disease 2026-02-27T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/54348552173253ab/arna-pharma-and-slate-run-pharmaceuticals-form-joint-venture-to-create-scaled-u-s-specialty-pharmaceutical-platform 2026-02-27T01:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/1825cac6e745e7df/world-first-stem-cell-therapy-for-spina-bifida-shows-safety-in-groundbreaking-fetal-surgery-trial 2026-02-27T01:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/7559ed052695debd/bayer-s-xofigo-plus-enzalutamide-reduces-death-risk-by-24-in-metastatic-prostate-cancer-trial 2026-02-26T21:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/59cb56da3f8ea356/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-of-tedopi-r-in-nsclc 2026-02-26T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/0d3506b1705ffe8d/first-patient-in-hampton-roads-receives-tricvalve-implant-in-fda-breakthrough-device-trial-for-severe-tricuspid-regurgitation 2026-02-26T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/3ccf95fc133468d7/tecovirimat-fails-to-show-efficacy-against-mpox-in-landmark-stomp-trial 2026-02-26T21:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/dbf626d83f03031f/chop-and-penn-medicine-develop-first-crispr-platform-for-direct-analysis-of-patient-aml-cells 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/5aa34d3b624b21dc/ella-ai-health-advocate-receives-irb-exemption-advancing-ethical-clinical-trial-recruitment 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/da194d6c17c89450/endra-s-taeus-liver-device-achieves-mri-level-consistency-in-masld-clinical-study 2026-02-26T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/b4374ac14baacf6e/pmv-pharma-s-rezatapopt-shows-promise-in-first-in-human-study-for-tp53-y220c-mutated-solid-tumors 2026-02-26T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/acd54152ac882ff9/boehringer-ingelheim-acquires-sitryx-s-novel-oral-immunometabolic-program-in-500m-deal 2026-02-26T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/9be00759888456c7/kairos-pharma-signs-term-sheet-to-acquire-two-clinical-stage-lung-cancer-assets-from-celyn-therapeutics 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/a906adf4f9e78004/gemmabio-doses-first-patient-in-phase-1-2-trial-of-next-generation-gene-therapy-gb221-for-spinal-muscular-atrophy-type-1 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/debdb9cb865ea4cd/quotient-sciences-expands-manufacturing-partnership-with-ipsen-for-ultra-rare-fop-treatment 2026-02-26T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/271750fcfda9b749/asahi-kasei-acquires-german-antiviral-specialist-aicuris-for-eur780-million-to-expand-infectious-disease-portfolio 2026-02-26T17:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/c07af71d42a9c62f/samchundang-secures-4-billion-european-glp-1-deal-with-breakthrough-patent-circumventing-technology 2026-02-26T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/b0bc0815e7b5411a/hotspot-therapeutics-demonstrates-promising-preclinical-results-for-novel-irf5-inhibitors-in-autoimmune-disease-treatment 2026-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3721d5b76025c6a/curanex-pharmaceuticals-completes-gmp-manufacturing-milestone-for-ulcerative-colitis-drug-candidate-phyto-n 2026-02-26T09:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/dada719eb4b465a1/india-s-technology-development-board-funds-indigenous-car-nk-cell-therapy-platform-for-cancer-and-leishmaniasis-treatment 2026-02-26T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/05eff4c51cfb9192/gsk-s-linerixibat-receives-priority-review-in-china-for-rare-liver-disease-related-pruritus 2026-02-26T09:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/6c55811ea08c3128/spectral-medical-s-tigris-trial-shows-significant-mortality-reduction-in-endotoxic-septic-shock-published-in-the-lancet 2026-02-26T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d4da52907702a836/mahzi-therapeutics-doses-first-patient-in-groundbreaking-gene-therapy-trial-for-pitt-hopkins-syndrome 2026-02-26T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/1c0e634a46829434/quantum-surgical-acquires-j-j-s-neuwave-medical-to-expand-robotic-cancer-treatment-platform 2026-02-26T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/9d9bde8c55604852/b-c-teen-becomes-first-patient-cured-of-chronic-granulomatous-disease-using-prime-editing-gene-therapy 2026-02-26T05:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/606436b0ab4ad241/novel-p53-targeting-drug-rezatapopt-shows-20-response-rate-in-phase-1-trial-across-multiple-cancer-types 2026-02-26T01:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/a007881f842d7387/fda-approves-numelvi-first-second-generation-jak-inhibitor-for-canine-allergic-dermatitis 2026-02-26T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/15a5252f46f739a0/optimi-health-launches-ibogaine-initiative-following-u-s-executive-order-on-psychedelic-drug-development 2026-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/37a7ee3706567310/melodia-therapeutics-secures-key-u-s-patent-for-novel-dpp1-inhibitor-mld-151 2026-02-25T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/ea19972520f3c408/leveragen-secures-japanese-patent-for-singularity-platform-single-domain-antibody-discovery-technology 2026-02-25T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/c10ac9ae9eb31cd0/nexus-precision-health-acquires-leal-health-to-scale-ai-powered-precision-medicine-platform 2026-02-25T21:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/5a58e4dee3e92215/fda-approves-first-oral-liquid-desmopressin-solution-for-central-diabetes-insipidus 2026-02-25T21:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/d451f726b51f6b97/alkermes-ceo-richard-pops-to-retire-after-35-year-leadership-blair-jackson-named-successor 2026-02-25T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/c033e00ed91ad460/breezebio-raises-60m-series-b-to-advance-precision-genetic-medicine-platform-and-type-1-diabetes-therapy 2026-02-25T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/413fe045d1e90bdf/cumberland-pharmaceuticals-launches-national-promotion-of-talicia-for-h-pylori-treatment 2026-02-25T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/d56848818334e349/slate-medicines-secures-130m-series-a-to-advance-novel-anti-pacap-migraine-therapy 2026-02-25T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/8f9a323a5f0a4b88/itm-to-present-pancreatic-neuroendocrine-tumor-subgroup-analysis-from-phase-3-compete-trial-at-enets-2026 2026-02-25T17:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/148451d4b597212e/enveric-biosciences-secures-patent-victory-as-abbvie-withdraws-challenge-following-1-2-billion-gilgamesh-acquisition 2026-02-25T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/923a00aed5ee5108/iqvia-acquires-charles-river-discovery-assets-to-expand-ai-driven-drug-development-platform 2026-02-25T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/711bdaf209cbd0a3/precisionlife-and-ovation-develop-first-genetic-biomarkers-to-predict-glp-1-therapy-response 2026-02-25T17:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/cc51c00eb0ff0a22/fda-accepts-viatris-supplemental-application-for-phentolamine-eye-drops-to-treat-presbyopia 2026-02-25T17:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/b3ab3db5a895f2dd/gsk-acquires-35pharma-for-950m-to-advance-potential-best-in-class-pulmonary-hypertension-treatment-hs235 2026-02-25T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/cc4e7aaca47190d1/northx-biologics-and-demeetra-form-strategic-partnership-to-accelerate-biologics-development-from-gene-to-gmp-manufacturing 2026-02-25T13:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/9dd9ddb7c84906ed/turkish-scientists-develop-computational-digital-scalpel-to-accelerate-drug-discovery-through-protein-allosteric-site-targeting 2026-02-25T13:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/5e7badf0c3b57513/pentixapharm-receives-fda-approval-for-cxcr4-targeted-radiotheranostic-program-in-blood-cancers 2026-02-25T13:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/aeb1253fc52a7a01/solascure-s-aurase-wound-gel-shows-22x-better-debridement-and-7x-faster-healing-in-chronic-wounds 2026-02-25T13:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/8319319e5978f97e/george-medicines-expands-global-reach-of-triple-combination-hypertension-drug-gmrx2-through-strategic-licensing-deals 2026-02-25T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/41944c44d632f1e7/steincares-and-shilpa-biologicals-form-strategic-partnership-to-expand-biosimilar-access-across-latin-america 2026-02-25T09:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/774e7c5908c1829f/merck-s-doravirine-islatravir-combination-demonstrates-non-inferiority-in-phase-3-hiv-treatment-trials 2026-02-25T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/c417353ae584cff7/turbine-raises-25-million-series-b-to-expand-ai-powered-virtual-biology-platform-into-immunology 2026-02-25T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/d8ed05034b1a1f7d/johnson-johnson-seeks-fda-approval-for-first-ever-treatment-of-rare-blood-disorder-waiha 2026-02-25T01:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/5b5fbf5c1e6efc16/polaroid-therapeutics-receives-ce-mark-for-novel-antimicrobial-wound-dressing-poltx-fiber 2026-02-25T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b901cec31e48439/honeywell-reduces-johnson-matthey-catalyst-technologies-acquisition-by-640-million 2026-02-25T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/101bc04626d57a5d/nih-funded-trial-achieves-70-reduction-in-hiv-incidence-through-digital-health-innovation-in-rural-east-africa 2026-02-24T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/a2ba13a90976fc5c/ucla-researchers-engineer-t-cells-to-overcome-glucose-starvation-in-solid-tumors-using-cellobiose-metabolism 2026-02-24T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/ca6bade72ab92b8d/arpa-h-awards-144-million-to-accelerate-human-healthspan-trials-targeting-aging-biology 2026-02-24T21:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/bcd35e7dbd862820/cosmos-health-strengthens-ai-drug-discovery-platform-with-appointment-of-athos-therapeutics-ceo-dr-dimitrios-iliopoulos 2026-02-24T21:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/5f7b32ac89a7c8b6/artelo-biosciences-reports-clinical-progress-across-three-drug-pipeline-in-2025 2026-02-24T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/faaa2f2860cf147f/invivyd-publishes-variant-agnostic-covid-19-protection-model-for-monoclonal-antibody-pemivibart 2026-02-24T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/d2746570511659f7/azitra-expands-atr-04-clinical-trial-to-md-anderson-cancer-center-for-egfr-inhibitor-associated-rash-treatment 2026-02-24T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/0021e5b1a1bbcd00/treace-medical-presents-positive-clinical-data-for-3d-bunion-correction-technologies-at-acfas-2026 2026-02-24T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/3fde938f3ce97eda/centauri-therapeutics-secures-ps6m-from-amr-action-fund-to-advance-novel-antibiotic-ctx-187-through-phase-i-trials 2026-02-24T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/7179a4f074dd134e/bloom-science-initiates-phase-1b-obesity-trial-of-bl-001-advancing-ketogenic-based-alternative-to-glp-1-therapies 2026-02-24T17:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/050f1578e07f9e0d/promatix-biosciences-reports-50-fold-potency-improvement-with-novel-bispecific-adc-for-colorectal-cancer 2026-02-24T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/68290e50fe691df8/onemednet-partners-with-risorius-to-advance-eeg-based-digital-biomarkers-for-cns-research 2026-02-24T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/808bdcbe7d8d1ff5/vico-therapeutics-advances-vo659-with-twice-annual-dosing-in-phase-1-2-trial-for-huntington-s-disease-and-spinocerebellar-ataxias 2026-02-24T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/f85c5712495a8f57/cf-pharmtech-receives-nmpa-acceptance-for-first-in-class-inhaled-pulmonary-fibrosis-treatment-icf004 2026-02-24T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/554160da872f428c/us-and-japan-maintain-stricter-alzheimer-s-drug-approval-standards-compared-to-global-markets 2026-02-24T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/44a9fde7a90b8ea6/cansino-biologics-secures-nmpa-approval-to-expand-menhycia-mcv4-vaccine-to-children-up-to-6-years-old 2026-02-24T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/a621d5f925c49a8d/edesa-biotech-s-paridiprubart-shows-27-mortality-reduction-in-phase-3-ards-study 2026-02-24T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/b60c1fbac189da8b/solascure-s-aurase-wound-gel-demonstrates-22x-faster-debridement-in-phase-ii-chronic-wound-trial 2026-02-24T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/98e9be1c33979ed2/slate-medicines-raises-130m-to-develop-novel-pacap-targeting-migraine-drug 2026-02-24T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/73360debea63cfc1/molnupiravir-demonstrates-77-efficacy-against-feline-infectious-peritonitis-in-clinical-trial 2026-02-24T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/237cb6d763d17d70/fda-grants-breakthrough-designation-to-orthonika-s-synthetic-total-meniscus-implant 2026-02-24T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/250c08f974c64b72/almirall-advances-etherna-s-intratumoral-mrna-therapy-lad116-to-clinical-development-for-non-melanoma-skin-cancer 2026-02-24T09:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/7a7908cba47033f8/hif-2a-inhibitor-casdatifan-demonstrates-15-month-progression-free-survival-in-advanced-kidney-cancer 2026-02-24T05:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/71c2a4b087adda20/smith-nephew-partners-with-si-bone-to-expand-pelvic-fracture-fixation-portfolio 2026-02-24T05:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/b2f41d63a87c8ebf/rytvela-shows-40-reduction-in-preterm-birth-rates-in-preclinical-study 2026-02-24T05:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/f1576fbf9ce3381b/fda-places-partial-clinical-hold-on-macrogenics-lorigerlimab-trial-following-severe-safety-events 2026-02-24T05:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/54c5bb2e425e46ac/kyntra-bio-s-fg-3246-adc-shows-promising-results-in-metastatic-prostate-cancer-combination-trial 2026-02-24T01:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/96aa175947698f85/astellas-and-vir-biotechnology-form-1-7-billion-strategic-partnership-for-psma-targeting-t-cell-engager-vir-5500-in-prostate-cancer 2026-02-24T01:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/3d0e02e5b6c6aaec/grove-biopharma-s-protein-like-polymers-successfully-degrade-undruggable-cancer-targets-myc-and-kras 2026-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/970b3bc839ac9467/bayer-sues-johnson-johnson-over-allegedly-false-prostate-cancer-drug-marketing-claims 2026-02-23T21:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/b706bb458dd0fb73/viiv-s-dovato-shows-lower-steatotic-liver-disease-risk-compared-to-biktarvy-in-hiv-patients 2026-02-23T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/d6657bb29b2498ea/fda-approves-allurion-swallowable-gastric-balloon-for-obesity-treatment 2026-02-23T21:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/ffb253020e4f3451/uk-mhra-approves-first-ever-treatment-for-non-cystic-fibrosis-bronchiectasis 2026-02-23T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/15042b1ec70f614d/dare-bioscience-receives-fda-clearance-for-phase-2-trial-of-dare-hpv-first-potential-treatment-for-persistent-high-risk-hpv-infection 2026-02-23T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/483a1546a6e76fce/blackstone-life-sciences-partners-with-johnson-johnson-to-advance-bleximenib-for-acute-myeloid-leukemia-treatment 2026-02-23T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/6f1bf8b1f35ac73b/angelini-pharma-partners-with-quiver-bioscience-in-120m-deal-to-advance-ai-driven-therapies-for-rare-genetic-epilepsies 2026-02-23T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/fb8052dc2e67e45b/surenano-science-acquires-glucapharm-advancing-second-generation-glp-1-drug-gep44-with-improved-tolerability 2026-02-23T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/d5b13a6bfd23a320/generate-biomedicines-targets-2-2-billion-valuation-in-ipo-as-ai-drug-discovery-platform-advances-severe-asthma-therapy 2026-02-23T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/ab9b678603c13a37/checkpoint-inhibitors-show-promise-for-hiv-positive-cancer-patients-across-multiple-studies 2026-02-23T17:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/c8ce95eb1ffc248a/bioxytran-partners-with-university-of-georgia-to-test-novel-h5n1-bird-flu-treatment 2026-02-23T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/3f233482eaf81e9f/transcode-therapeutics-publishes-breakthrough-rig-i-agonist-study-enabling-tumor-selective-cancer-immunotherapy 2026-02-23T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/eb058dbd57cff604/alps-group-reports-positive-safety-data-for-autologous-nk-cell-therapy-in-nine-patient-case-series 2026-02-23T17:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/1a9bd31cd8c8a321/eu-launches-eur225-million-initiative-to-accelerate-next-generation-influenza-vaccine-development 2026-02-23T13:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/b7fef9b858d15dc8/morepen-laboratories-secures-91-million-cdmo-contract-from-global-pharmaceutical-company 2026-02-23T09:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/60d5a45bddf9d9c0/uk-government-launches-ps100m-funding-initiative-to-strengthen-life-sciences-manufacturing-and-r-d-competitiveness 2026-02-23T07:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/82790d3af5ec6cb6/virion-therapeutics-vron-0200-shows-sustained-anti-hbv-immunity-in-phase-1b-trial 2026-02-23T01:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/9c3d088bb7391297/til-therapy-expands-access-across-us-health-systems-following-fda-approval-for-advanced-melanoma 2026-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b1833c9009c41736/gyder-surgical-s-pin-less-hip-navigation-system-debuts-in-us-commercial-surgery 2026-02-22T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/e5b8094c4efb8d18/redmile-group-invests-49-million-in-scholar-rock-as-apitegromab-nears-regulatory-resubmission 2026-02-22T21:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/e6c678dabb96bd1d/phase-3-trial-demonstrates-cannabis-extract-ver-01-significantly-reduces-chronic-low-back-pain 2026-02-22T17:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/4b9505ba05ce3351/brazil-india-partnership-advances-pertuzumab-development-for-her-2-metastatic-breast-cancer 2026-02-22T13:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/a55443a715051986/aurobindo-pharma-targets-10000-metric-tonnes-annual-penicillin-g-production-amid-government-policy-support 2026-02-22T09:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/7782f77627ec1f07/biogen-completes-phase-2-trial-of-biib091-for-relapsing-multiple-sclerosis 2026-02-21T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/96b70129884002f4/tirzepatide-shows-promise-for-alcohol-use-disorder-treatment-in-preclinical-study 2026-02-21T12:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/8bb5f50778966489/cdsco-completes-comprehensive-audit-of-90-of-india-s-cough-syrup-manufacturers-following-safety-concerns 2026-02-21T12:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/e38f8e0d9edc500f/mhra-pauses-pathways-clinical-trial-following-safety-concerns-for-children-and-young-people 2026-02-21T04:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/0330b6dc6558a5c1/enhanced-car-nk-cell-therapy-shows-superior-tumor-control-through-novel-costimulatory-design 2026-02-20T21:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/832ec5538b98c5a7/adarx-pharmaceuticals-to-present-phase-1-2-data-for-onvuzosiran-sirna-therapy-at-aaaai-2026-meeting 2026-02-20T21:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/ecfd9208ac531ccc/telefonica-vithas-and-ufv-pioneer-quantum-computing-for-cancer-drug-discovery-targeting-braf-v600e-mutation 2026-02-20T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/d04c45821f7f8f71/gvrp-and-yurogen-biosystems-form-strategic-partnership-to-advance-antibody-discovery-in-india 2026-02-20T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/c6eb0da65f15f84a/japan-approves-world-s-first-ips-cell-based-therapies-for-parkinson-s-disease-and-heart-failure 2026-02-20T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/b8c009d3d1d1a4a6/insufficient-source-material-for-roche-leukemia-treatment-fda-approval 2026-02-20T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/3191e0b5cc7cced0/fda-grants-first-gras-approval-for-rubisco-protein-as-plantible-foods-advances-lemna-based-ingredient 2026-02-20T14:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/1e34f668143ae346/milken-institute-and-ann-theodore-foundation-launch-575000-grant-for-mtor-inhibitor-trial-in-cutaneous-sarcoidosis 2026-02-20T14:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/5c084b244dad481b/southampton-researchers-launch-clinical-trial-using-diagnostic-tampons-for-early-ovarian-cancer-detection 2026-02-20T14:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/5f98304fb1bfc3e6/chugai-launches-japan-s-first-gene-therapy-for-duchenne-muscular-dystrophy 2026-02-20T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/2d8ca71eecd97361/prothena-reports-q4-2025-results-as-neurodegeneration-pipeline-advances-with-major-partnerships 2026-02-20T05:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/de1bd196e5efd35e/starton-therapeutics-initiates-phase-2a-trial-of-star-lld-for-relapsed-refractory-multiple-myeloma 2026-02-20T05:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/68e417f60e40ca9f/indian-regulatory-committee-recommends-dpco-exemption-for-first-indigenous-antibiotic-nafithromycin 2026-02-20T05:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/824a3eb19c2b03e2/former-novartis-cmo-john-tsai-appointed-global-head-of-r-d-at-daiichi-sankyo 2026-02-20T05:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/025646ed8e5de6a4/myriad-genetics-validates-firstgene-r-prenatal-screen-with-exceptional-accuracy-across-multiple-testing-components 2026-02-20T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/0d758cf3ea9120ef/xenon-pharmaceuticals-faces-critical-phase-3-data-readout-for-epilepsy-drug-azetukalner-in-march 2026-02-20T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/c1e7e5afd59ae802/johnson-johnson-explores-20-billion-sale-of-depuy-synthes-orthopedics-unit 2026-02-20T01:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/3a01442668a2a59e/biontech-files-patent-lawsuit-against-moderna-over-next-generation-covid-19-vaccine-technology 2026-02-20T01:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/ce95135296ce4b04/next-life-sciences-advances-two-non-hormonal-male-contraceptives-into-phase-ii-clinical-trials 2026-02-20T01:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/df4a10fdea01b6f9/pylarify-becomes-first-blockbuster-radiodiagnostic-with-1-06-billion-in-2024-sales 2026-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce1e5ac770e8e097/stereotactic-radiation-improves-quality-of-life-for-patients-with-multiple-brain-metastases 2026-02-19T21:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/bcdc61f2562f566a/step-pharma-receives-eur2-5-million-eic-grant-to-advance-ctps1-inhibitor-dencatistat-for-gynecological-cancers 2026-02-19T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/a8fefe550478c53d/xeris-biopharma-files-patent-infringement-lawsuit-to-protect-recorlev-against-generic-competition 2026-02-19T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/ba44f660a33b38d3/novartis-ag-completes-exit-from-indian-operations-with-345-million-stake-sale-to-investment-consortium 2026-02-19T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/b70a0b2495ef703d/chryscapital-acquires-majority-stake-in-novartis-india-for-rs-1450-crore 2026-02-19T21:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/45e3c3075e6a727f/boehringer-ingelheim-partners-with-niper-raebareli-to-advance-pharmaceutical-research-and-education-in-india 2026-02-19T21:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/9f9f6c7d63b0d14f/lario-therapeutics-secures-2-4m-to-advance-neuronal-calcium-channel-platform-for-parkinson-s-and-ptsd 2026-02-19T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/d8f08b6a5c050fb4/omvoh-demonstrates-three-year-steroid-free-remission-in-crohn-s-disease-patients 2026-02-19T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/d9df6d2ff87bbe12/takeda-s-entyvio-shows-promise-in-pediatric-ulcerative-colitis-with-47-remission-rate-in-phase-3-kepler-trial 2026-02-19T21:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/4119a42c8996a0f2/nexeos-bio-receives-fda-clearance-for-phase-ii-iii-trial-of-ntx-1024-in-rare-eye-disease 2026-02-19T21:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/687e50ba1506a657/fda-expands-age-range-for-staar-surgical-s-evo-icl-to-include-patients-up-to-60-years-old 2026-02-19T21:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/c26e4248cf943a10/altesa-biosciences-secures-75-million-series-b-to-advance-first-in-class-copd-exacerbation-treatment 2026-02-19T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/fd05a47058273c35/bristol-myers-squibb-launches-patent-infringement-case-against-johnson-johnson-over-car-t-cell-therapy-in-europe 2026-02-19T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/e8b824101e2cfde8/rituxan-receives-japanese-approval-for-autoimmune-hemolytic-anemia-treatment 2026-02-19T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/575d90bcf2bf660a/klothea-bio-launches-phase-1b-trial-of-akl003-mrna-therapy-targeting-longevity-protein-klotho 2026-02-19T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/245067c0fd34b0e4/ten63-therapeutics-raises-45m-to-advance-ai-driven-drug-discovery-platform-targeting-previously-undruggable-proteins 2026-02-19T17:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/d6c267153b7d5b2d/kilgourmd-hair-loss-system-shows-rapid-results-in-menopausal-women-clinical-trial 2026-02-19T17:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/404d59b9632bc58c/breath-diagnostics-receives-fda-breakthrough-device-designation-for-onebreath-platform-to-assess-postoperative-pneumonia-risk 2026-02-19T17:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/7f791be7a12faeaa/bioaffinity-technologies-reports-146-growth-in-cypath-lung-test-sales-as-clinical-case-studies-demonstrate-diagnostic-value 2026-02-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5561a93051f704b1/northstrive-biosciences-advances-el-32-manufacturing-for-muscle-preservation-in-glp-1-therapy-patients 2026-02-19T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/e240742040ef5085/dror-ortho-design-receives-fda-510-k-clearance-for-ai-powered-sleep-based-orthodontic-system 2026-02-19T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa470158e4f15208/fda-grants-priority-review-to-garetosmab-for-ultra-rare-bone-disease-fibrodysplasia-ossificans-progressiva 2026-02-19T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/e4659a960d6ed2fb/yoltech-s-yolt-202-gene-editing-therapy-shows-promising-results-in-alpha-1-antitrypsin-deficiency-trial 2026-02-19T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/6cac5cde4d96609e/healwell-ai-and-well-health-launch-welltrust-platform-to-accelerate-clinical-trial-patient-recruitment 2026-02-19T13:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/8d77028dc7f418b6/catheter-precision-divests-atherectomy-assets-for-15000-to-focus-on-electrophysiology-growth 2026-02-19T10:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/37ea18b8a09f3ea5/biomarin-raises-850-million-in-debut-bond-offering-to-finance-amicus-therapeutics-acquisition 2026-02-19T09:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/a20daf7d680ddd90/eupraxia-pharmaceuticals-raises-55-million-to-advance-eosinophilic-esophagitis-treatment 2026-02-19T05:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/19643b405ae150ec/organigram-completes-eur107-3-million-acquisition-of-sanity-group-with-british-american-tobacco-investment 2026-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17a1a5ca908d5ca1/sensei-biotherapeutics-acquires-faeth-therapeutics-for-200m-to-advance-pi3k-akt-mtor-pathway-inhibitor-piktor 2026-02-19T01:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/0810435355c52738/alembic-therapeutics-launches-pivya-first-novel-uti-antibiotic-in-decades-for-us-market 2026-02-19T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/1c7568dff4fc6099/avidity-s-del-desiran-shows-promise-for-myotonic-dystrophy-type-1-in-phase-1-2-marina-trial-published-in-nejm 2026-02-19T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/2d7199a95bd5a9ad/cyanocapture-and-persist-ai-partner-to-build-world-s-first-robotic-gmp-facility-for-oral-protein-and-peptide-drugs 2026-02-19T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/3db713faf89acc24/terumo-launches-revolutionary-blood-collection-tubes-using-snake-venom-derived-technology-in-japan 2026-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0d21ec01ca2d2f5a/monkeypox-treatment-pipeline-expands-with-mrna-vaccines-and-novel-therapeutics-from-major-pharma-companies 2026-02-18T21:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/0534dd9e56c068a3/zealand-pharma-reports-positive-phase-1a-results-for-novel-kv1-3-channel-blocker-zp9830-in-autoimmune-disease-development 2026-02-18T21:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/a707e94498b9aedc/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-in-38m-deal-for-gut-targeted-therapy 2026-02-18T21:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/60777e32cd553a1a/personalized-mrna-vaccine-shows-durable-immune-responses-in-triple-negative-breast-cancer-trial 2026-02-18T21:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/600ba503c108f815/sift-biosciences-raises-3-7m-to-develop-memory-t-cell-immunotherapy-platform-for-cold-tumors 2026-02-18T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/481a2f23ed470041/ankyra-therapeutics-unveils-first-in-class-cd137-anchored-immunotherapy-ank-203-with-promising-preclinical-anti-tumor-activity 2026-02-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/cb7505aa317d3863/israeli-biotech-starget-pharma-raises-18m-to-advance-ai-driven-radiopharmaceutical-cancer-therapies 2026-02-18T21:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/266db9ef63ed6eaa/tarsus-pharmaceuticals-appoints-former-allergan-ceo-david-pyott-to-board-of-directors 2026-02-18T21:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/b31120ed61318ac5/feinstein-institutes-scientists-transform-detrimental-immune-element-into-novel-sepsis-and-rheumatoid-arthritis-therapy 2026-02-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/7f1d47aa5eba206a/korsana-biosciences-emerges-with-175m-to-develop-next-generation-alzheimer-s-antibody-therapy 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/a72f3443d7b9fa33/oxford-completes-phase-0-trial-of-igf-antibody-xentuzumab-in-prostate-cancer-patients 2026-02-18T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/64b82e59988b8ea7/newbiologix-publishes-breakthrough-hek293-cell-line-data-showing-two-fold-improvement-in-gene-therapy-vector-production 2026-02-18T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/b8f2dcfbbaad3c8a/rna-interference-therapy-market-expands-with-90-drugs-in-development-across-40-companies 2026-02-18T17:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/7489c24ba3d25b3d/pluri-secures-china-patent-for-large-scale-immune-cell-manufacturing-platform 2026-02-18T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/896f455d61f80df9/grunenthal-initiates-phase-i-trial-of-novel-nav-1-8-inhibitor-for-non-opioid-pain-management 2026-02-18T17:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/f9e7f591083da83a/oncohost-breakthrough-enables-integration-of-serum-and-plasma-proteomic-data-for-enhanced-cancer-biomarker-research 2026-02-18T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/fbdddfe34c6d06dd/zydus-lifesciences-secures-fda-approval-for-pediatric-pah-treatment-while-launching-respiratory-device-in-india 2026-02-18T17:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/2e6984d027803070/unnatural-products-partners-with-novartis-in-1-7-billion-macrocyclic-peptide-deal-for-cardiovascular-therapeutics 2026-02-18T17:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/dd18bfe4b06fea20/fda-grants-breakthrough-device-designation-to-two-rapid-tests-for-critical-drug-resistant-pathogens 2026-02-18T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/542f15e3b0f18dca/acrivon-therapeutics-launches-clia-certified-laboratory-to-advance-precision-medicine-development 2026-02-18T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/3f95766d35e75808/rezon-bio-secures-fda-approval-for-commercial-biosimilar-manufacturing-at-warsaw-duchnice-facility 2026-02-18T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/d2642df2c0e6ee1b/india-launches-national-cancer-clinical-trials-alliance-and-liquid-biopsy-foundation-to-address-growing-cancer-burden 2026-02-18T17:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/dd7295e3aaf690bb/xingimaging-selected-to-lead-imaging-operations-for-landmark-alzheimer-s-tau-platform-phase-ii-trial 2026-02-18T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/6e337e12fe4da2a2/trellus-health-secures-six-month-extension-with-johnson-johnson-for-ibd-digital-platform 2026-02-18T12:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/8df8db47645bbf56/pharmacelera-secures-eur6m-to-accelerate-quantum-ai-drug-discovery-platform-in-us-market 2026-02-18T12:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/212e255d4cbfcac6/ai-powered-drug-discovery-startup-peptris-secures-7-7m-series-a-to-advance-clinical-pipeline 2026-02-18T12:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/a940d7a162ded185/chinese-scientists-achieve-14-million-fold-expansion-of-cancer-fighting-nk-cells-from-single-stem-cell 2026-02-18T05:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/aa5dcf5d5dfb133f/new-zealand-s-pharmac-proposes-funding-for-two-chronic-lymphocytic-leukemia-combination-therapies 2026-02-18T01:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/58a120e77e2e09df/watchmaker-genomics-licenses-crispr-cas9-technology-from-caribou-biosciences-for-novel-ngs-library-normalization 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/1e6c66359e8e4352/seek-labs-receives-2-million-usda-grant-to-develop-crispr-based-mutation-resistant-avian-flu-therapeutic 2026-02-18T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/6d4abc04ad001d7e/klotho-neurosciences-secures-australian-patent-for-novel-gene-therapy-targeting-motor-neuron-diseases 2026-02-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5dc9d9fe0e2f599/mayo-clinic-becomes-first-u-s-institution-to-deploy-magnetic-nanoparticle-hyperthermia-technology-for-cancer-research 2026-02-17T21:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/d3ee969f46ffe7cc/calibr-skaggs-and-kainomyx-launch-gates-foundation-backed-collaboration-to-develop-novel-antimalarial-drugs-targeting-parasite-cytoskeleton 2026-02-17T21:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/1e1d2611bffdfb2e/rna-targeting-small-molecules-emerge-as-new-frontier-in-drug-discovery-with-major-pharma-partnerships 2026-02-17T21:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/822bd1f561123d50/ucla-researchers-develop-nanoparticle-based-gene-editing-platform-for-cystic-fibrosis-treatment 2026-02-17T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/305dd9e121bd7a20/pharmaceutical-industry-faces-growing-revenue-pressures-from-pricing-and-reimbursement-delays 2026-02-17T21:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/92b4fa97d8709c56/kansas-city-partners-launch-integrated-theranostics-platform-for-adult-and-pediatric-patients 2026-02-17T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/7e95dd97039c428a/fred-hutch-scientists-develop-first-human-monoclonal-antibodies-to-block-epstein-barr-virus-infection 2026-02-17T21:02:17+00:00 hourly 0.9 https://trial.medpath.com/news/725e745ba3a7cd62/terns-pharmaceuticals-gains-institutional-interest-as-stock-surges-830-following-pipeline-updates 2026-02-17T17:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/9aa95d191c569b4f/largest-metabolomic-study-of-car-t-cell-therapy-reveals-new-biomarkers-for-predicting-severe-neurotoxicity 2026-02-17T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/f07340dfad164fa5/omeros-reports-breakthrough-primate-study-results-for-novel-aml-therapeutic-oncotox-aml 2026-02-17T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/586ccb63f91fff6f/cyrano-therapeutics-reports-positive-phase-2-results-for-cyr-064-in-persistent-post-viral-smell-loss 2026-02-17T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/4d69e4cbb4e5382b/scinai-immunotherapeutics-completes-acquisition-of-recipharm-israel-and-forms-strategic-cdmo-partnership 2026-02-17T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/4c532154ec3b7e33/texas-community-cancer-center-launches-first-car-t-program-outside-hospital-setting 2026-02-17T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/247e41773583fa04/andelyn-biosciences-partners-with-drake-rayden-foundation-to-manufacture-aav-gene-therapy-for-rare-nkh-disease 2026-02-17T17:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/e7a7a37135d6299e/essential-pharma-acquires-ventavis-for-primary-pulmonary-hypertension-from-bayer-ag 2026-02-17T17:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/2116745e8f76f178/diakonos-oncology-s-doc1021-clears-first-safety-review-in-phase-2-glioblastoma-trial 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/6a6667827a80ca00/evogene-partners-with-queensland-university-to-develop-ai-driven-cancer-therapeutics-for-chemotherapy-resistant-lung-cancer 2026-02-17T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/3506a27a01df6427/sana-biotechnology-appoints-brian-piper-as-cfo-ahead-of-key-clinical-data-readouts 2026-02-17T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/8f39f1ffaa35c0c1/retia-medical-receives-fda-clearance-for-argos-infinity-cardiovascular-intelligence-platform 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/3f9d852cee82ed67/portal-diabetes-receives-fda-breakthrough-designation-for-implantable-insulin-pump-system 2026-02-17T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/055fabf773f115dc/fda-accepts-tirabrutinib-nda-for-rare-brain-lymphoma-under-accelerated-approval-pathway 2026-02-17T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/ebe8390f3bc8c03d/fda-accepts-bristol-myers-squibb-s-iberdomide-nda-for-multiple-myeloma-testing-new-regulatory-flexibility 2026-02-17T17:02:26+00:00 hourly 0.9 https://trial.medpath.com/news/21aa6432fb2bb723/nimbus-therapeutics-advances-novel-sik2-inhibitors-for-inflammatory-bowel-disease-with-dual-anti-inflammatory-and-mucosal-healing-mechanism 2026-02-17T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/f6f50d09dc660263/instanosis-receives-fda-breakthrough-device-designation-for-rapid-xylazine-urine-test 2026-02-17T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/4e98016c90f2bf5b/viiv-healthcare-advances-ultra-long-acting-hiv-pipeline-with-third-generation-integrase-inhibitor-vh184-data-at-croi-2026 2026-02-17T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/767fc6af6e8471ba/fda-approved-drug-amd3100-overcomes-immunotherapy-resistance-in-rare-liver-cancer 2026-02-17T17:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/f29bbadfb2601878/salipro-biotech-secures-key-u-s-patent-for-membrane-protein-platform-extending-protection-until-2042 2026-02-17T13:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/b77fd45cef3ffb55/sanofi-and-teva-s-duvakitug-shows-sustained-efficacy-in-phase-2b-maintenance-study-for-inflammatory-bowel-disease 2026-02-17T13:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/b5c8462051ca286d/circio-s-circvec-platform-achieves-50-fold-gene-expression-enhancement-in-eye-disease-applications 2026-02-17T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/170aadbad3e692fd/roche-appoints-cancer-researcher-mark-dawson-to-lead-pharma-research-division 2026-02-17T13:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/9c27768624bdaca8/nuclera-and-leadxpro-partner-to-accelerate-ai-driven-drug-discovery-for-challenging-membrane-proteins 2026-02-17T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/489438037d2f4255/teijin-and-aska-pharmaceutical-partner-to-develop-ai-driven-gynecological-therapeutics 2026-02-17T13:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/b93569e0392f85e9/beactica-secures-eur2-5-million-eic-grant-to-advance-first-in-class-glioblastoma-therapy-bea-17-toward-clinical-trials 2026-02-17T13:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/66998e6cc48b10a6/prognica-labs-and-nextgen-immuno-therapeutics-form-strategic-partnership-to-advance-ai-powered-precision-immunology 2026-02-17T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/8bad3bfd0205b204/fda-considers-revoking-safety-status-of-processed-carbohydrates-as-health-industry-faces-major-regulatory-and-corporate-shifts 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/1f48ace7bfc606b9/danaher-acquires-masimo-for-9-9-billion-to-expand-patient-monitoring-portfolio 2026-02-17T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/e0305d96d7744a4d/oeb-6-emerges-as-new-manufacturing-standard-for-ultra-potent-oncology-drugs-and-adcs 2026-02-17T03:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/9ce2affffb48e7a4/edwards-lifesciences-withdraws-anti-copycat-policy-as-eu-closes-antitrust-investigation 2026-02-17T01:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/efe6538731dd53ca/uk-veterinary-regulator-confirms-safety-profile-of-canine-osteoarthritis-drug-librela-following-comprehensive-review 2026-02-16T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/671662901370b3ce/single-dmt-dose-shows-rapid-lasting-antidepressant-effects-in-treatment-resistant-depression-trial 2026-02-16T21:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/66dc6228c7294852/tozaro-secures-ps6-million-to-reduce-gene-therapy-manufacturing-costs-with-smart-polymer-platform 2026-02-16T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/0f3b5ef8b1eff15e/zemcelpro-receives-nub-status-1-in-germany-enabling-immediate-hospital-reimbursement-applications 2026-02-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/613dd6ba507aa73f/lilly-s-retevmo-shows-significant-event-free-survival-benefit-in-early-stage-ret-fusion-positive-lung-cancer 2026-02-16T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/c475a63a97f89d81/artios-pharma-strengthens-leadership-team-with-three-key-appointments-to-advance-dna-damage-response-pipeline 2026-02-16T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/6ac4880fb5bf9a51/lex-diagnostics-receives-fda-510-k-clearance-for-ultra-fast-point-of-care-pcr-system 2026-02-16T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/4fe1c436e9f1ac2f/fda-clears-first-foxg1-gene-therapy-for-clinical-trials-in-rare-neurodevelopmental-disorder 2026-02-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/1e16496f948bcb70/chinese-researchers-report-first-case-of-type-2-diabetes-reversal-using-stem-cell-therapy 2026-02-16T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/75598c5b8e618a84/seismic-consortium-secures-eur23-5-million-to-develop-next-generation-minimally-invasive-brain-surgery-technologies 2026-02-16T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/babf58beecf4b8c5/bio-techne-s-ella-platform-receives-ce-ivd-marking-expanding-rapid-immunoassay-access-in-european-clinical-laboratories 2026-02-16T13:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/387c5c8ab38df8ef/harness-therapeutics-advances-first-in-class-huntington-s-disease-drug-hrn001-toward-clinical-trials 2026-02-16T13:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/f322cca42e02b9e4/eisai-s-e2086-receives-orphan-drug-designation-in-japan-for-narcolepsy-treatment 2026-02-16T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/6b0873a7c7578151/immunic-raises-400m-to-advance-first-in-class-multiple-sclerosis-therapy-toward-commercial-launch 2026-02-16T13:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/5c0b7ce5dd1e3347/quidelortho-partners-with-lifotronic-technology-to-expand-global-immunoassay-portfolio 2026-02-16T09:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/749648d88c6748df/cstone-s-novel-trispecific-antibody-cs2009-receives-fda-clearance-for-phase-ii-trial-in-advanced-solid-tumors 2026-02-16T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/ec5586e03ffdae13/neogenomics-launches-pantracer-pro-to-streamline-advanced-solid-tumor-testing 2026-02-15T21:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/38acb26ded0d1545/uae-partners-with-insilico-medicine-to-launch-ai-driven-drug-discovery-initiative 2026-02-15T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/14684bf9065f25c0/phathom-pharmaceuticals-refocuses-on-gastroenterology-projects-profitability-by-second-half-2026 2026-02-15T12:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/e57b60639384555f/iran-advances-to-7th-place-globally-in-regenerative-medicine-with-six-new-atmp-approvals 2026-02-15T12:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/6cb3d51964bed5a2/oncores-medical-raises-a-27-million-to-advance-real-time-breast-cancer-surgery-imaging-technology 2026-02-15T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/fdfcf858682f540a/nhs-launches-world-s-largest-mental-health-study-to-develop-personalized-treatments-for-severe-mental-illness 2026-02-15T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/08b1fbaa3c4da68a/alkem-laboratories-enters-cardiovascular-device-market-with-eur99-4-million-occlutech-acquisition 2026-02-14T21:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/edcbad40be631dd4/nxera-pharma-licenses-gpcr-targeted-program-to-investment-firm-backed-spin-out-company 2026-02-14T21:01:31+00:00 hourly 0.9 https://trial.medpath.com/news/40ba328d45ed6b16/zydus-lifesciences-secures-fda-approval-for-generic-ammonium-lactate-cream-for-dry-skin-conditions 2026-02-14T17:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/bcf8bbead13df38c/fda-confirms-single-pivotal-study-standard-for-drug-approval-accelerating-cinclus-pharma-s-gerd-treatment-path 2026-02-14T04:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/92c32a9e5a387fcf/galecto-raises-316-3-million-in-public-offering-to-advance-blood-cancer-therapeutics-pipeline 2026-02-14T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/96dd70d6948511e9/moderna-pivots-to-international-markets-after-fda-rejects-flu-vaccine-application 2026-02-14T04:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/09f6f7a2ae48bdea/deuterium-depletion-shows-promise-as-novel-cancer-therapy-through-gene-expression-modulation 2026-02-14T04:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/3d91fd0f6ca70209/nk-cell-engager-development-faces-mounting-setbacks-as-beone-medicines-and-novartis-discontinue-programs 2026-02-14T04:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/488d8d16617aca9a/advanced-therapies-enable-long-term-survival-in-multiple-myeloma-patients-through-second-stem-cell-transplants 2026-02-13T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/9377f0ddf90587a0/bracco-and-acist-medical-systems-launch-next-generation-acist-pro-diagnostic-system-in-europe 2026-02-13T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/d1ccb610f8a8abd6/abbvie-advances-multi-target-ibd-strategy-with-combination-therapies-and-subcutaneous-skyrizi-data-expected 2026-02-13T21:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/b6f58a47784b9f6c/icmr-study-confirms-six-month-oral-tb-regimens-reduce-costs-while-improving-outcomes-for-drug-resistant-cases 2026-02-13T21:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/0ac11f0cd0398348/hcw-biologics-and-wy-biotech-launch-joint-venture-trimmune-to-advance-cancer-immunotherapy-hcw11-006 2026-02-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/5094f2d7725220b6/ema-recommends-withdrawal-of-levamisole-medicines-from-eu-market-due-to-serious-brain-side-effects 2026-02-13T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/ba5fbd683dde9d26/aurobindo-s-acrotech-receives-fda-approval-for-adquey-first-non-steroidal-pde4-inhibitor-for-atopic-dermatitis 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/daf7a767243b2033/china-medical-system-partners-with-insilico-medicine-for-ai-drug-discovery-advances-complement-inhibitor-to-clinical-trials 2026-02-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/7683271003d5cd4c/nasus-pharma-raises-15-million-to-advance-needle-free-epinephrine-treatment-for-anaphylaxis 2026-02-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/5189552cb685bc1c/precision-biologics-presents-preclinical-data-on-novel-pb-223-adc-targeting-truncated-core-2-glycans-in-solid-tumors 2026-02-13T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/e39d487f12a5dfb4/advanced-biomed-launches-120-patient-study-to-validate-3d-cell-culture-platform-for-precision-cancer-treatment 2026-02-13T17:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/fa4b88c0c38e705a/astrazeneca-s-breztri-shows-significant-lung-function-improvements-in-phase-iii-asthma-trials 2026-02-13T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/b7110bb1d7d449a3/iterum-therapeutics-expands-orlynvah-market-access-while-fda-requires-additional-clinical-trial-for-step-down-therapy 2026-02-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9f427e3446d2df9/ai-integration-and-ps45-million-investment-signal-new-era-for-alzheimer-s-drug-discovery 2026-02-13T12:38:50+00:00 hourly 0.9 https://trial.medpath.com/news/2ce8ecaa4112b0c3/national-cancer-institute-launches-multi-cancer-blood-test-trial-at-eight-centers-nationwide 2026-02-13T08:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/d5640b91818f339e/genfit-receives-20m-milestone-as-iqirvo-exceeds-200m-sales-threshold-in-first-year 2026-02-13T04:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/0984f578410e9fd6/japan-grants-world-first-pharmaceutical-approval-for-human-milk-based-fortifier-in-neonatal-care 2026-02-13T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/701ef0ef7c8c5455/innovent-initiates-phase-3-trial-of-ibi354-her2-adc-for-first-line-her2-positive-breast-cancer-treatment 2026-02-13T04:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/809b922d04a1b2fb/lundbeck-s-bocunebart-meets-primary-endpoint-in-phase-iib-migraine-prevention-trial 2026-02-13T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/8432ad4c6aeccda5/neuroendocrine-tumor-pipeline-shows-promise-with-75-therapies-in-development-and-recent-fda-approvals 2026-02-13T04:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/1d13fd989f806401/ptc-therapeutics-withdraws-translarna-nda-for-duchenne-muscular-dystrophy-following-fda-feedback 2026-02-13T04:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/e559dee517dd28cc/european-regulators-recommend-approval-of-first-whim-syndrome-treatment 2026-02-13T04:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/f7734fffc0413c9e/tempus-partners-with-median-technologies-to-integrate-fda-cleared-ai-lung-cancer-screening-tool 2026-02-13T04:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/f2f4b64f5b73f209/inventiva-s-lanifibranor-achieves-dual-endpoints-in-nash-trial-analysts-project-2-6b-peak-sales 2026-02-13T01:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/f422cdbd9335f872/abbvie-challenges-medicare-price-controls-on-botox-citing-plasma-derived-product-exemption 2026-02-12T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/4409f713f097e199/major-study-finds-no-link-between-covid-19-mrna-vaccination-during-pregnancy-and-neurodevelopmental-disorders-in-children 2026-02-12T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/b87ce55fed568cb5/centivax-begins-phase-1-trial-of-universal-flu-vaccine-targeting-all-strains 2026-02-12T21:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/98c976d9b0eaad90/arvinas-appoints-randy-teel-as-ceo-following-first-successful-protac-pivotal-trial 2026-02-12T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/1f485803cd07f268/biolife-solutions-expands-into-500-million-cytokines-market-through-exclusive-qkine-partnership 2026-02-12T17:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/ea15982b27a6b96f/aardvark-therapeutics-establishes-dermatology-subsidiary-ardia-to-advance-novel-psoriasis-treatment-dia-615 2026-02-12T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/374fce9be9902204/zeon-corporation-invests-in-digital-chemistry-pioneer-chemify-to-accelerate-automated-drug-discovery 2026-02-12T17:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/3046b3682961622c/oncotelic-therapeutics-expands-global-patent-protection-for-ot-101-tgf-b-antisense-therapy-across-cns-and-neurology-applications 2026-02-12T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/a0445f00bb5cdce2/discus-trial-results-prompt-nhs-to-reduce-chemotherapy-cycles-for-advanced-bladder-cancer 2026-02-12T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/fbc12541bb8d3989/caredx-s-ai-powered-alloheme-test-detects-aml-and-mds-relapse-41-days-earlier-than-standard-methods 2026-02-12T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/94d7e5ec928ee557/apertura-gene-therapy-launches-open-aperture-program-to-democratize-access-to-cns-targeting-aav-capsid 2026-02-12T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/70f45becf14861f2/nanoviricides-files-orphan-drug-application-for-nv-387-mpox-treatment-amid-current-therapy-failures 2026-02-12T17:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/c71fd5f31b6ac724/totus-medicines-to-present-updated-phase-1-data-for-novel-covalent-pi3ka-inhibitor-tos-358-at-esmo-tat-congress 2026-02-12T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/237d0bf496ba1036/grace-therapeutics-awaits-fda-decision-on-gtx-104-for-aneurysmal-subarachnoid-hemorrhage-with-april-2026-pdufa-date 2026-02-12T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/be7706fefa7adbde/bridgebio-s-oral-infigratinib-achieves-breakthrough-results-in-phase-3-achondroplasia-trial 2026-02-12T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/0a77c66f2cba567d/encora-therapeutics-receives-fda-510-k-clearance-for-wearable-essential-tremor-device 2026-02-12T17:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/34a5e840489043f3/bridgebio-s-oral-dwarfism-drug-infigratinib-achieves-best-in-class-results-in-pivotal-achondroplasia-trial 2026-02-12T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/56eb3a6b4e022e30/neupulse-secures-ps3-million-to-advance-tourette-syndrome-wearable-device-toward-2026-launch 2026-02-12T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/78da5c2532b681e7/biological-e-receives-who-phase-ii-pre-qualification-for-novel-oral-polio-vaccine-type-2 2026-02-12T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/398a2dff638f0316/fda-grants-fast-track-designation-to-99mtc-maraciclatide-for-interstitial-lung-disease-imaging 2026-02-12T13:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/d39cfc2a7330fb88/valar-labs-publishes-ai-breakthrough-for-pancreatic-cancer-treatment-selection-in-journal-of-clinical-oncology 2026-02-12T09:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/86c0c3307ce8b0c3/arkbio-receives-fda-clearance-for-phase-2-trial-of-novel-anti-fibrotic-drug-ak3280-in-idiopathic-pulmonary-fibrosis 2026-02-12T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/29722119364734e8/researchers-identify-genetic-mechanism-behind-rare-blood-clotting-in-johnson-johnson-and-astrazeneca-covid-vaccines 2026-02-12T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/656620e98e337eca/fda-approves-novocure-s-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/2c85ff356dc435a6/fda-issues-warnings-over-sexual-enhancement-products-containing-undeclared-prescription-drug-ingredients 2026-02-12T05:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/7f3cade7f222cb80/fda-approves-optune-pax-for-locally-advanced-pancreatic-cancer-first-new-treatment-in-nearly-30-years 2026-02-12T05:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/6607a8b905e0afa5/pharmap-2026-to-showcase-patient-centric-medicine-and-regulatory-harmonization-in-amsterdam 2026-02-12T02:30:41+00:00 hourly 0.9 https://trial.medpath.com/news/7fa58fe72c6c65d8/speed-based-brain-training-reduces-dementia-risk-by-25-in-20-year-clinical-trial 2026-02-12T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/20f3649782a518e7/pl-bioscience-secures-japan-pmda-certification-for-cell-culture-media-advancing-regenerative-medicine-development 2026-02-12T01:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/22e08796dc3c00e0/crystalys-therapeutics-appoints-former-horizon-ceo-tim-walbert-to-board-as-gout-drug-advances-through-phase-3-trials 2026-02-12T01:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/0b647c082d636872/vivos-inc-advances-radiogel-r-precision-radionuclide-therapy-toward-fda-clinical-trials 2026-02-11T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/1cee0a6d56fcb9ed/claudin18-2-adc-race-intensifies-as-astrazeneca-prepares-pivotal-data-while-chinese-competitors-advance 2026-02-11T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fd3a3bdbafdeb103/slamf6-emerges-as-novel-immune-checkpoint-target-for-cancer-immunotherapy 2026-02-11T21:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/cdc2d721c4b30ae2/iveena-delivery-systems-initiates-first-in-human-phase-1-trial-of-ivmed-85-for-myopia-prevention 2026-02-11T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/416816a3623f0bb7/oregon-state-researchers-develop-gold-nanoparticles-for-safe-low-power-melanoma-therapy 2026-02-11T21:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/e6c2430396118b25/zura-bio-advances-dual-target-bispecific-tibulizumab-through-phase-2-trials-in-autoimmune-diseases 2026-02-11T21:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/b20cebee84755f5f/edgewise-therapeutics-advances-sevasemten-phase-3-trial-for-duchenne-muscular-dystrophy-with-enhanced-statistical-power 2026-02-11T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/39d2a4859d344fe2/gelteq-and-healthy-extracts-form-strategic-partnership-to-scale-gel-based-nutraceutical-manufacturing 2026-02-11T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/13f515360681d2e9/thermo-fisher-scientific-partners-with-datavant-to-enhance-real-world-data-connectivity-in-clinical-research 2026-02-11T21:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/39aca1afdc04bad0/uk-regulators-impose-major-restrictions-on-chikungunya-vaccine-following-fatal-adverse-events 2026-02-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/3cd113e7bf85d66d/bioxytran-s-prolectin-m-achieves-100-viral-clearance-in-phase-2-trial 2026-02-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/23e78b7f1f4973a7/northwestern-scientists-develop-advanced-human-spinal-cord-organoids-to-test-revolutionary-dancing-molecules-therapy 2026-02-11T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/6e90ebcc4d84c76e/evogene-systasy-and-lmu-university-hospital-launch-ai-driven-collaboration-to-target-neutrophil-mediated-inflammatory-diseases 2026-02-11T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/7eb4aa8c0a02301b/stoke-therapeutics-initiates-first-in-human-trial-of-stk-002-for-rare-genetic-eye-disease-adoa 2026-02-11T17:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/0f313058a37fed70/rapid-dose-therapeutics-launches-quickstrip-medical-cannabis-in-brazil-following-anvisa-approval 2026-02-11T17:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/49d596cd8cf124f1/denovo-biopharma-partners-with-orygen-for-phase-2-trial-of-novel-glutamate-targeting-drug-in-early-psychosis 2026-02-11T17:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/263aeb66c4dae9d4/german-pharma-industry-warns-us-drug-price-regulations-could-delay-medicine-launches-in-europe 2026-02-11T13:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/59682237f0c1fead/upstream-bio-s-verekitug-shows-significant-efficacy-in-phase-2-severe-asthma-trial 2026-02-11T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/8cc4dccc4013d508/microbiotica-s-mb310-achieves-63-clinical-remission-rate-in-phase-1b-ulcerative-colitis-trial 2026-02-11T13:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/caf247045cf64854/arctic-therapeutics-initiates-phase-iia-trial-of-novel-acetylcholinesterase-inhibitor-at-004-for-acne-vulgaris 2026-02-11T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/9f55d647d6f248fb/erlysign-receives-fda-breakthrough-device-designation-for-revolutionary-saliva-based-oral-cancer-detection-test 2026-02-11T13:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/7bb4be7ec8b8d3ce/gossamer-bio-awaits-pivotal-seralutinib-data-for-pulmonary-arterial-hypertension-this-month 2026-02-11T13:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/8021e3c1b6c62635/eccogene-reports-positive-phase-1b-results-for-oral-glp-1-agonist-elecoglipron-in-chinese-patients-with-obesity 2026-02-11T05:02:26+00:00 hourly 0.9 https://trial.medpath.com/news/4dc335dbfa654cb7/vesalio-secures-ce-mark-for-neurovascular-devices-targeting-cerebral-vasospasm-and-stroke-treatment 2026-02-11T05:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/3e3607eb7b42a4d4/chugai-pharmaceutical-licenses-araris-aralinq-technology-for-next-generation-adc-development 2026-02-11T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/49ecf3eb1d28a701/psma-pet-ct-guided-salvage-radiotherapy-shows-promising-5-year-outcomes-in-post-prostatectomy-patients 2026-02-11T01:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/b1f42412fa680d05/thx-pharma-and-biocodex-forge-eur173-million-licensing-deal-for-rare-neurological-disease-treatments 2026-02-10T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/d7ae00cb9e224eed/4basebio-appoints-amy-walker-as-ceo-to-lead-commercial-growth-in-synthetic-dna-manufacturing 2026-02-10T21:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/1efab5f2433cf82e/car-t-cell-therapy-shows-promise-for-alzheimer-s-disease-in-first-neurodegenerative-application 2026-02-10T21:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/9776372a32751df1/canary-speech-and-intermountain-health-launch-first-ai-driven-vocal-biomarker-study-for-multiple-sclerosis-detection 2026-02-10T21:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/afe9ff74135d4f69/fda-approves-ipledge-rems-modifications-to-reduce-isotretinoin-access-barriers-while-maintaining-safety 2026-02-10T21:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/50ad8060028ab190/bvi-s-finevision-hp-trifocal-iol-successfully-implanted-in-first-us-procedures-following-fda-approval 2026-02-10T21:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/7004bc37bfe6acef/fda-clears-phase-2b-trial-of-teverelix-for-advanced-prostate-cancer-patients-with-high-cardiovascular-risk 2026-02-10T21:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/a1a73eb62babafce/active-biotech-s-tasquinimod-myelofibrosis-trial-resumes-after-fda-approval-of-protocol-amendment 2026-02-10T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/753671edd86c0611/nih-halts-rivaroxaban-arm-of-major-stroke-prevention-trial-due-to-safety-concerns 2026-02-10T21:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/e53084981caf1794/regeneron-unveils-first-in-class-phase-3-data-for-novel-cat-and-birch-allergy-treatments-at-aaaai-2026 2026-02-10T17:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/10bc841c81e8acbf/moderna-signs-five-year-strategic-agreement-with-mexico-for-mrna-manufacturing-and-vaccine-supply 2026-02-10T17:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/152ebf7c714b9aff/university-at-buffalo-researchers-develop-inhalable-nanoparticle-system-for-tuberculosis-treatment 2026-02-10T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/c9f3109350c54ba2/septerna-advances-mrgprx2-inhibitor-sep-631-to-clinical-testing-for-chronic-urticaria-and-mast-cell-disorders 2026-02-10T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/e4e2175144925a90/arraypatch-secures-eur1-6m-in-first-close-of-seed-round-to-advance-microneedle-patch-for-nail-fungus-treatment 2026-02-10T17:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/7c1ed4cbea649e57/calbiotech-and-liquid-biosciences-form-strategic-partnership-to-advance-ai-driven-diagnostic-development 2026-02-10T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/e73f794642de93cd/qnovia-s-respirx-inhaled-nicotine-therapy-shows-promise-in-phase-1-trial-with-cigarette-like-delivery-speed 2026-02-10T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/119f268a7aae7e1e/merck-partners-with-calla-lily-clinical-care-to-advance-novel-intravaginal-drug-delivery-platform 2026-02-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/d9cfaaa18a2b55ac/iterion-therapeutics-initiates-first-in-class-wnt-b-catenin-inhibitor-trial-for-relapsed-osteosarcoma 2026-02-10T17:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/3adaf3955cfe515f/hoth-therapeutics-gdnf-shows-superior-efficacy-over-semaglutide-in-preclinical-obesity-study 2026-02-10T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/14221ed42159c863/circular-genomics-secures-exclusive-ip-rights-for-circrna-based-alzheimer-s-blood-test-from-leading-research-institutions 2026-02-10T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/db93e98cfcb01455/university-of-missouri-launches-first-on-campus-radiopharmaceutical-clinical-trial-using-eye90-microspheres-for-liver-cancer 2026-02-10T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/abd2f0739e8ae7fa/quince-therapeutics-engages-lifesci-capital-for-strategic-review-as-stock-surges-over-300 2026-02-10T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbd5d1a4e89f540c/daratumumab-demonstrates-76-reduction-in-relapse-risk-for-nmosd-in-phase-3-dawn-trial 2026-02-10T13:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/249972c36768dc82/irbm-develops-novel-allosteric-inhibitor-targeting-zika-virus-protease-with-broad-flavivirus-potential 2026-02-10T13:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/82374a2000641454/claudin-18-2-targeted-therapy-market-set-to-exceed-800-million-by-2030-as-pipeline-expands-beyond-gastric-cancer 2026-02-10T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/5320f75ee73bb28f/gyala-therapeutics-launches-first-in-class-cd84-targeted-car-t-trial-for-relapsed-acute-leukemias 2026-02-10T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/8e3159cf8277d145/national-cancer-institute-launches-preclinical-study-of-ivermectin-s-anticancer-properties 2026-02-10T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/f61da9ab8311a05e/yatiri-bio-achieves-100-accuracy-in-predicting-aml-drug-response-using-ai-driven-biomarker-platform 2026-02-10T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/6df2a065f4cb7768/kainova-therapeutics-raises-32m-cad-to-advance-gpcr-targeting-cancer-and-inflammation-therapies 2026-02-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/f0dcb79e339d0504/syngene-international-partners-with-johns-hopkins-university-to-accelerate-early-stage-drug-discovery-programs 2026-02-10T09:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/53baf8c7f26cb9e6/lupin-settles-90-million-patent-dispute-with-astellas-to-secure-mirabegron-market-access 2026-02-10T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/2894824d81eaf86d/fresenius-kabi-and-phlow-corp-launch-first-end-to-end-u-s-manufacturing-partnership-for-epinephrine-injection 2026-02-10T01:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/fbf160243db483ec/merrylife-biomedical-advances-tml-6-to-phase-2-following-positive-safety-results-in-alzheimer-s-disease-trial 2026-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7e1e56c686b4e14/sparingvision-completes-dosing-in-phase-i-ii-trial-for-gene-agnostic-retinitis-pigmentosa-therapy-spvn06 2026-02-09T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/48b79655892dd502/pila-pharma-advances-proof-of-concept-study-for-rare-pain-disorder-erythromelalgia 2026-02-09T21:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/d0ddf640d90b31b8/diff-biotech-s-novel-nasal-spray-influenza-vaccine-receives-clinical-trial-approval-in-china 2026-02-09T21:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/e15c22f21baa7580/time-restricted-feeding-reduces-crohn-s-disease-activity-by-40-in-randomized-trial 2026-02-09T21:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/e89f1ed6b9cc4641/uv-smart-receives-first-ever-fda-clearance-for-uv-c-tee-probe-disinfection-system 2026-02-09T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/c648579b02c84924/fda-grants-rmat-designation-to-krystal-biotech-s-kb707-gene-therapy-for-advanced-non-small-cell-lung-cancer 2026-02-09T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/a4158632f4a80a88/quantx-biosciences-raises-85m-series-b-to-advance-oral-stat6-and-il-17-inhibitors 2026-02-09T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/670fe37ffd0d91d9/aerska-secures-39m-series-a-to-advance-rna-brain-delivery-platform-for-neurological-diseases 2026-02-09T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/1ca994f146065ca1/nextpoint-therapeutics-receives-fda-clearance-for-first-in-class-b7-h7-targeted-t-cell-engager-npx372 2026-02-09T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/216ba2fb4f23538f/world-s-first-dual-payload-adc-kh815-enters-clinical-trials-with-biodlink-manufacturing-support 2026-02-09T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/8fdda322bc53e13d/cellarisbio-secures-patent-and-launches-micro-tag-platform-for-real-time-drug-target-engagement 2026-02-09T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/05cf10332593d32b/transmedics-receives-fda-approval-for-landmark-heart-preservation-trial-to-challenge-standard-transplant-methods 2026-02-09T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/38d5943809c09d63/lunai-bioworks-partners-with-clinical-stage-company-to-apply-ai-analysis-to-phase-2-metastatic-colorectal-cancer-trial-data 2026-02-09T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/de05b28e8f131151/ethris-partners-with-german-center-for-infection-research-to-develop-next-generation-mrna-vaccines 2026-02-09T13:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/5f277ac7de70268e/arecor-therapeutics-advances-ultra-concentrated-insulin-at278-toward-phase-ii-trial-in-2026 2026-02-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/d4ee239aaf9f1918/breye-therapeutics-reports-promising-phase-1b-results-for-oral-diabetic-retinopathy-drug-danegaptide 2026-02-09T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/89cdfc6aa5e1a5f9/pandorum-technologies-secures-18m-series-b-to-advance-exosome-based-regenerative-therapies 2026-02-09T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/a6fae24925e84b6e/memo-therapeutics-partners-with-csl-in-328-million-deal-for-recombinant-polyclonal-igg-technology 2026-02-09T09:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/091d6bb2c1d6375d/hku-researchers-demonstrate-finerenone-s-potential-in-treating-premature-ovarian-insufficiency 2026-02-09T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/60da0535fb466640/bristol-myers-squibb-partners-with-evinova-to-deploy-ai-driven-clinical-trial-optimization-platform 2026-02-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/991a94d0cf48ac2c/avacta-therapeutics-promotes-francis-wilson-to-chief-scientific-officer-to-lead-pre-cision-platform-development 2026-02-09T09:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/a6fbf93043f17586/cue-biopharma-enters-critical-phase-following-immunoscape-partnership-and-december-2025-financing 2026-02-09T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/2ccc5203b3fd70f5/phytolon-receives-fda-approval-for-natural-beetroot-red-food-coloring-marking-major-regulatory-milestone 2026-02-09T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/3609689f2eb484cb/algorae-pharmaceuticals-expands-generic-medicine-portfolio-through-strategic-partnership-with-cadila 2026-02-09T05:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/872f4e53ba884d24/wilson-disease-pipeline-shows-promise-with-alxn1840-completing-phase-iii-trial-and-five-companies-advancing-novel-therapies 2026-02-09T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/aab90fb2df0e92b3/fda-clears-intuitive-surgical-s-da-vinci-5-system-for-advanced-cardiac-procedures 2026-02-09T01:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/e368a0389ef8fa15/aurobindo-pharma-receives-11-procedural-observations-from-us-fda-at-telangana-manufacturing-facility 2026-02-08T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/e873ee7f9caa3b40/crispr-gene-drive-technology-successfully-reverses-antibiotic-resistance-in-bacterial-populations 2026-02-08T05:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/2fb443ce270e365f/lupin-receives-fda-clearance-for-two-key-facilities-following-successful-regulatory-inspections 2026-02-08T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/b033c6b6eaf87ed6/lupin-s-solosec-shows-92-95-cure-rate-in-phase-3-trichomoniasis-trial-expanding-treatment-options-for-common-sti 2026-02-08T01:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/42fa5e2f1963cf91/lupin-secures-tentative-fda-approvals-for-generic-tadalafil-and-testosterone-gel-targeting-2-9-billion-combined-market 2026-02-08T01:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/35a7c427a1e57ad3/icmr-initiates-phase-i-trial-for-indigenous-kyasanur-forest-disease-vaccine 2026-02-07T21:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/58bb797bc67a431b/japanese-scientists-develop-oral-compound-mic-628-to-reset-circadian-rhythms-and-combat-jet-lag 2026-02-07T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/c4ba15b2902f5ef0/smx-secures-250-million-capital-extension-through-2028-to-advance-supply-chain-verification-platform 2026-02-07T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/6863c39d6b0cbbab/shilpa-medicare-files-first-us-transdermal-patch-anda-for-rotigotine-targeting-112-million-market 2026-02-07T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/a806cfad68ead1fc/ps1bn-london-cancer-hub-expansion-approved-to-boost-uk-life-sciences-research 2026-02-07T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/30d2c118d2fc70e5/breckenridge-pharmaceutical-partners-with-medichem-solutions-to-expand-injectable-portfolio-for-hospital-markets 2026-02-07T01:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/9806b3d9f5577727/lumosa-s-lt3001-shows-functional-improvements-in-phase-2-trials-for-acute-ischemic-stroke 2026-02-07T01:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/77dd48b2e701fbf1/bracco-imaging-enters-cell-therapy-manufacturing-with-microbubble-based-cell-selection-technology 2026-02-07T01:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/ce0985dd57512d04/hemex-health-receives-fda-breakthrough-device-designation-for-sickle-cell-disease-diagnostic-test 2026-02-07T01:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/989f21f3b8eed0c9/synact-pharma-completes-enrollment-in-phase-2b-trial-of-resomelagon-for-newly-diagnosed-rheumatoid-arthritis 2026-02-07T01:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/09fd2630f509cb26/cvs-health-expands-biosimilar-strategy-dropping-amgen-and-lilly-bone-disease-treatments-from-formularies 2026-02-06T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/b4ec58c6308b1669/fda-required-to-provide-detailed-q1-q2-sameness-feedback-under-new-federal-law 2026-02-06T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/166803579ad93eee/opko-health-and-entera-bio-expand-partnership-to-develop-first-oral-long-acting-pth-therapy-for-hypoparathyroidism 2026-02-06T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/b0f05699a733b7c7/new-classification-system-predicts-immunotherapy-response-in-liver-cancer-patients-with-b-catenin-mutations 2026-02-06T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/150467d27c641d51/delonix-bioworks-receives-dual-regulatory-clearance-for-novel-menb-vaccine-dx-104-in-china-and-australia 2026-02-06T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/6c156a6681f31597/pulmovant-completes-enrollment-in-phase-2-trial-of-mosliciguat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2026-02-06T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/bba1d10ba0fc4968/priovant-s-brepocitinib-shows-significant-efficacy-in-rare-skin-disease-trial-advancing-to-phase-3 2026-02-06T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/c2bd8b321ac8f85b/neurophet-receives-third-fda-510-k-clearance-for-ai-powered-alzheimer-s-imaging-analysis-software 2026-02-06T17:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/cf7cb08794e88a8b/fda-clears-first-dedicated-3t-mri-system-for-neonatal-imaging 2026-02-06T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/c0faa120c57a279e/bc-platforms-partners-with-omicsbank-to-expand-access-to-multi-omics-data-from-india-and-uae 2026-02-06T09:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/b55989bc6dba0b39/otsuka-pharmaceutical-secures-exclusive-rights-to-sky-labs-cuffless-blood-pressure-monitor-for-japan-market 2026-02-06T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/b6574f3c30a79eaf/pharmaresearch-receives-fda-clearance-for-phase-1-trial-of-nano-anticancer-drug-prd-101 2026-02-06T09:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/4a38369f700a2670/regeneron-advances-phase-2-trial-of-mibavademab-for-functional-hypothalamic-amenorrhea 2026-02-06T09:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/2b4edfb5fb6a31ef/pyc-therapeutics-reports-progress-across-rna-therapy-pipeline-with-strong-financial-position 2026-02-06T09:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/ccde2cff6a59d5be/china-nmpa-approves-velsipity-for-moderately-to-severely-active-ulcerative-colitis 2026-02-06T09:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/eb26fb6bdd33740e/pfizer-reports-strong-q2-2025-performance-with-pipeline-advances-and-raised-guidance 2026-02-06T05:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/2adfb7eae359f7c6/iit-bombay-develops-gentler-t-cell-recovery-method-to-enhance-car-t-cell-therapy-efficiency 2026-02-06T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/48be3cf050df0fc3/fagron-expands-global-pharmaceutical-compounding-network-with-strategic-acquisitions-in-brazil-and-hungary 2026-02-06T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/3673812341f10048/spruce-biosciences-reports-six-year-data-showing-tralesinidase-alfa-preserves-cognitive-function-in-sanfilippo-syndrome-type-b 2026-02-06T01:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/c1b649847eeb51f1/real-world-data-shows-amtagvi-achieves-44-response-rate-in-advanced-melanoma-exceeding-clinical-trial-results 2026-02-06T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/7484be3698c95550/ixico-appoints-new-chief-commercial-officer-to-accelerate-neuroscience-imaging-business-growth 2026-02-06T01:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/fb0af962371fe6ac/fda-mandates-genetic-testing-for-xeloda-and-5-fu-to-prevent-fatal-toxicities-in-dpd-deficient-patients 2026-02-06T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/22572ccdde5edfd4/abcuro-s-ulviprubart-misses-primary-endpoints-in-inclusion-body-myositis-trial-shows-promise-in-mild-to-moderate-patients 2026-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e49898b45b07da2/urate-lowering-treatment-reduces-cardiovascular-risk-in-gout-patients-by-9 2026-02-05T21:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/6587057a3c95fa78/fda-approved-heart-drug-dronedarone-shows-promise-as-novel-lymphoma-treatment-through-usp11-enzyme-targeting 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/1c82a2c56c1c4109/adarx-pharmaceuticals-appoints-donald-fong-as-chief-medical-officer-to-lead-rna-therapeutics-pipeline 2026-02-05T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/e17a5f7e59b463c0/menstrual-blood-hpv-testing-achieves-comparable-accuracy-to-clinician-sampling-in-large-chinese-study 2026-02-05T21:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/103592dd3db7574c/fda-implements-sweeping-policy-changes-to-accelerate-drug-approvals-and-transform-regulatory-landscape 2026-02-05T21:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/fa3ff0d6f7fb3ec6/eurofins-cdmo-alphora-partners-with-uk-company-to-develop-revolutionary-adc-manufacturing-platform 2026-02-05T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/667688c196666a19/infleqtion-advances-quantum-enabled-biomarker-discovery-for-precision-oncology-to-final-phase-of-wellcome-leap-challenge 2026-02-05T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/e19e3ddec9bf4342/fda-approves-vybrique-first-sildenafil-oral-film-for-erectile-dysfunction-treatment 2026-02-05T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/e6d95b36b7bc839f/sonorous-neurovascular-receives-fda-breakthrough-device-designation-for-bosstent-to-treat-pulsatile-tinnitus 2026-02-05T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/db4d8c6bcd5380b0/crohn-s-disease-clinical-trials-show-promising-pipeline-with-novel-therapies-advancing-through-development 2026-02-05T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/995b2bf85da04734/new-market-analysis-reveals-global-phenylketonuria-clinical-trials-landscape-and-strategic-opportunities 2026-02-05T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/29b0f0c7cebbe33c/photonpharma-initiates-phase-1-trial-of-innocell-autologous-immunotherapy-for-recurrent-ovarian-cancer 2026-02-05T17:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/444ddf03515a9637/glp-1-receptor-agonists-reduce-amputation-risk-and-cardiovascular-events-in-high-risk-diabetes-patients 2026-02-05T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/52111dc57adfd0ee/point-of-care-testing-for-hepatitis-b-dna-shows-high-accuracy-in-clinical-trial-expanding-access-to-diagnosis-and-treatment 2026-02-05T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/7440aec65d1bc846/alvotech-reports-positive-results-for-entyvio-biosimilar-in-pivotal-pharmacokinetic-study 2026-02-05T13:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/0c7752f0a427a911/crest-2-trial-shows-carotid-revascularization-fails-to-improve-cognitive-function-in-asymptomatic-patients 2026-02-05T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/9ee82aa1b5507cd1/novartis-streamlines-oncology-pipeline-discontinues-six-phase-1-cancer-programs 2026-02-05T09:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/3c0d0cb95708bf11/university-of-liverpool-partners-with-bpgbio-to-advance-ai-driven-drug-discovery-platform 2026-02-05T09:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/f35eac19e0993609/orthocell-advances-us-commercial-strategy-following-fda-approval-for-nerve-repair-device 2026-02-05T09:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/716243eee3cbae30/delaware-court-narrows-moderna-s-patent-defenses-in-8-2-billion-arbutus-lnp-technology-dispute 2026-02-05T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/ff7b731fc41cbdd4/jcr-pharmaceuticals-presents-promising-blood-brain-barrier-data-for-rare-disease-therapies-at-worldsymposium-2026 2026-02-05T05:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/90f96804eff71831/jupiter-endovascular-completes-spirare-ii-trial-enrollment-for-vertex-pulmonary-embolectomy-system 2026-02-05T00:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/f34d9355c511237c/sovateltide-shows-92-success-rate-in-phase-iv-stroke-trial-demonstrating-significant-functional-recovery 2026-02-05T00:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/ef00daf359f3e65b/metavia-s-ai-driven-analysis-confirms-vanoglipel-s-therapeutic-targets-for-mash-and-type-2-diabetes 2026-02-05T00:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/06ea043a06bf618c/fastest-trial-shows-mixed-results-for-factor-viia-in-acute-intracerebral-hemorrhage-signals-promise-in-early-treatment-subgroups 2026-02-05T00:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/156290c5544eae08/oncolytic-virus-therapy-pipeline-expands-with-100-companies-developing-novel-cancer-treatments 2026-02-05T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/03e738941a0a22cf/abbott-s-next-generation-cardiomems-hero-reader-receives-fda-approval-for-heart-failure-monitoring 2026-02-05T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/31be7deec7114d21/daiichi-sankyo-initiates-first-in-human-trial-of-ds3790-novel-cd37-targeted-adc-for-b-cell-lymphoma 2026-02-04T21:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/e75ff2cf927f41fa/liposomal-amphotericin-b-shows-comparable-efficacy-to-triazoles-in-invasive-aspergillosis-treatment 2026-02-04T21:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/1629c1c902f96c04/qt-sense-secures-eur4m-to-advance-quantum-nanodiamond-platform-for-real-time-cellular-drug-discovery 2026-02-04T21:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/2a9c7eb82b803fc9/intra-arterial-alteplase-after-thrombectomy-shows-significant-improvement-in-stroke-recovery-outcomes 2026-02-04T20:58:24+00:00 hourly 0.9 https://trial.medpath.com/news/ff61ec57c61abc72/primegen-us-secures-1-5-billion-spac-merger-to-advance-triple-activated-stem-cell-platform-for-acute-liver-injury 2026-02-04T17:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/6fea9a06568d0293/first-in-human-study-shows-trx103-cell-therapy-accelerates-immune-recovery-in-mismatched-stem-cell-transplants 2026-02-04T17:28:34+00:00 hourly 0.9 https://trial.medpath.com/news/5f5e3e9ae1e7600d/nigeria-launches-first-immunotherapy-trial-for-colorectal-cancer-in-sub-saharan-africa 2026-02-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/9d855d6e7d5e0e0b/third-arc-bio-raises-52-million-series-a-extension-to-advance-precision-immune-modulation-platform 2026-02-04T17:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/7a9a32b7da1c5f03/aprea-therapeutics-appoints-eugene-kennedy-as-chief-medical-advisor-following-early-clinical-success-with-wee1-inhibitor 2026-02-04T17:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/7c1dcd33b6cd32d5/axon-neuroscience-s-aadvac1-selected-for-two-major-nih-funded-platform-trials-in-alzheimer-s-and-psp 2026-02-04T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/9fee421b7836916d/oxford-biomedica-secures-five-year-commercial-supply-deal-with-bristol-myers-squibb-for-car-t-vector-manufacturing 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/7c8ee4c23a30bcb7/ai-powered-spatial-biology-analysis-reveals-new-insights-into-nsclc-immunotherapy-response 2026-02-04T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/005cda6b096edb3c/affinia-therapeutics-receives-fda-clearance-to-begin-phase-1-2-trial-of-aftx-201-gene-therapy-for-rare-heart-disease 2026-02-04T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/f1363fadf0e0093d/dewpoint-therapeutics-initiates-first-in-human-trial-of-novel-beta-catenin-condensate-modulator-dptx3186 2026-02-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/dc32c19cc8fb9636/novartis-faces-first-profit-decline-in-decade-as-key-drug-patents-expire 2026-02-04T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/53425792cd0d775f/aminex-therapeutics-initiates-phase-1b-2-trial-of-novel-polyamine-targeting-cancer-therapy-amxt-1501-plus-dfmo 2026-02-04T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/5df8032b4bbde0bb/biodexa-secures-exclusive-license-for-novel-molecular-glue-mtx240-to-target-tki-resistant-gist 2026-02-04T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/3b74f0e82d3f660f/addex-therapeutics-publishes-breakthrough-data-on-mglu7-targeting-for-anxiety-and-ptsd-treatment 2026-02-04T17:24:14+00:00 hourly 0.9 https://trial.medpath.com/news/cb7c1b22d18325b4/evogene-and-shanghai-lishan-biopharmaceuticals-announce-exclusive-global-licensing-deal-for-bmc128-microbiome-cancer-therapy 2026-02-04T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/ccc5dfb04512031c/kodiak-sciences-to-present-final-phase-1b-results-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-02-04T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/533d9b8abedf8c90/hologic-s-aptima-hpv-assay-receives-fda-approval-for-primary-cervical-cancer-screening 2026-02-04T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/03998eff1e82f859/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2026-02-04T17:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/b1a69c9ba408e1f1/amgen-refuses-fda-request-to-withdraw-rare-disease-drug-tavneos-amid-data-integrity-concerns 2026-02-04T17:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/816989f2fa2fb595/neomorph-begins-first-clinical-trial-of-molecular-glue-cancer-treatment-neo-811-for-kidney-cancer 2026-02-04T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/1e4b7e8832551ad3/mhra-implements-major-clinical-trial-reform-with-mandatory-ivd-assessment-starting-april-2026 2026-02-04T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/48ecbd23d4d0e248/uk-regulatory-body-finds-sanofi-in-breach-over-unsubstantiated-rsv-therapy-claims-against-pfizer 2026-02-04T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/b8ae898422fa3749/forus-health-receives-cdsco-approval-for-ai-powered-diabetic-retinopathy-screening-tool-in-india 2026-02-04T13:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/b658c1178bd76624/repotrectinib-demonstrates-durable-activity-in-ntrk-fusion-positive-solid-tumors-with-promising-outcomes-in-tki-pretreated-patients 2026-02-04T13:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/5ca8742101f613ca/defence-therapeutics-to-showcase-accum-r-intracellular-delivery-platform-at-world-adc-europe-2026 2026-02-04T13:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/b0c07d2bb42146a4/cdr-life-appoints-dimitrios-chondros-as-chief-medical-officer-to-advance-t-cell-engager-platform 2026-02-04T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/05f1810cb1b907de/major-cancer-research-coalition-launches-12-million-initiative-to-advance-early-detection-of-deadly-cancers 2026-02-04T09:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/9e515f21e5cdc15e/cizzle-biotechnology-secures-canadian-patent-for-ciz1b-lung-cancer-biomarker-test 2026-02-04T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/e539afb103e1b87a/mink-therapeutics-identifies-inkt-cell-depletion-as-key-mechanism-in-advanced-idiopathic-pulmonary-fibrosis 2026-02-04T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/b043a38c56c1ec38/single-dose-hiv-vaccine-candidate-induces-neutralizing-antibodies-in-nonhuman-primates 2026-02-04T01:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/9ed8279f9dbcc2e5/sanegenebio-secures-1-5-billion-rnai-licensing-deal-with-genentech 2026-02-04T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/4f798bc6e0745f33/dash-bio-opens-24000-square-foot-glp-compliant-facility-to-accelerate-drug-development-bioanalysis 2026-02-04T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/1fcea1ee12a37d20/marvel-biosciences-secures-japanese-patent-for-autism-spectrum-disorder-therapeutic-mb-204 2026-02-04T01:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/cd6d2ef8dc866105/quest-diagnostics-launches-noninvasive-blood-test-for-multiple-myeloma-residual-disease-monitoring 2026-02-04T01:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/db67788e4f429af3/boehringer-ingelheim-discontinues-cystic-fibrosis-gene-therapy-while-advancing-eur25-billion-r-d-investment-plan 2026-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bfca45e6994a2293/agc-biologics-seattle-facility-receives-brazilian-gmp-certification-opening-access-to-40-billion-south-american-market 2026-02-03T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/5d6a05fd6bf5b06a/cepi-partners-with-samsung-biologics-to-strengthen-global-vaccine-manufacturing-for-future-pandemics 2026-02-03T21:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/2882288b0262b48b/fda-issues-early-alert-for-impella-heart-pump-sensor-malfunction-linked-to-22-patient-injuries 2026-02-03T21:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/b6e801d08f2fd5a1/zipbio-and-meiragtx-partner-to-develop-ai-designed-gene-therapy-for-geographic-atrophy 2026-02-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/cab771c9391bb290/mapi-pharma-reports-promising-phase-ii-results-for-ga-depot-in-primary-progressive-multiple-sclerosis 2026-02-03T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/f269975358873b3d/neomorph-doses-first-patient-in-phase-1-2-trial-of-neo-811-molecular-glue-degrader-for-advanced-renal-cell-carcinoma 2026-02-03T21:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/b7c9aa0d61dc1555/gentherm-submits-fda-510-k-application-for-first-of-kind-patient-warming-and-securement-system 2026-02-03T17:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/3216bcc5dceb8373/tsc-life-receives-fda-clearance-for-pediatric-use-of-fluido-r-compact-blood-and-fluid-warming-system 2026-02-03T17:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/1d318e188738461c/allarity-therapeutics-opens-phase-2-trial-combining-stenoparib-with-temozolomide-for-relapsed-small-cell-lung-cancer 2026-02-03T17:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/a27b4824ab95d6f1/pyxis-oncology-appoints-thomas-civik-as-interim-ceo-to-advance-micvo-cancer-therapy-development 2026-02-03T17:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/407c09e6740cf953/metformin-shows-promise-in-slowing-age-related-macular-degeneration-progression 2026-02-03T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/11ab370933ad3af1/merck-forecasts-2026-revenue-below-wall-street-estimates-as-patent-cliff-looms 2026-02-03T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/0bbc38ad5e8e3aec/hookipa-pharma-sells-oncology-assets-including-hpv-and-kras-targeted-therapies-to-neotrail-therapeutics 2026-02-03T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/c1062df8c637d768/china-nmpa-approves-promega-s-msi-detection-kit-as-companion-diagnostic-for-keytruda 2026-02-03T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/cec9644ff2a46ead/sk-bioscience-licenses-novel-rsv-monoclonal-antibody-from-gates-medical-research-institute 2026-02-03T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/e655c9056518fc8e/valo-health-names-novo-nordisk-veteran-karin-conde-knape-as-chief-scientific-officer 2026-02-03T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/f2ada8034bda2662/alzheon-s-valiltramiprosate-shows-promising-biomarker-results-in-phase-3-alzheimer-s-trial 2026-02-03T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/94a020b75f5cd56c/abbvie-submits-upadacitinib-for-vitiligo-treatment-potentially-first-systemic-therapy-for-autoimmune-skin-disease 2026-02-03T17:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/0f9e5f27f10271a4/daiichi-sankyo-discontinues-claudin-6-adc-ds-9606-following-strategic-portfolio-review 2026-02-03T17:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/38fb1ae32ab60a71/baysient-expands-precision-dosing-platform-to-17-inflammatory-disease-indications-with-idose-gen7-0-launch 2026-02-03T17:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/3de175e6b40721b4/preciseonco-consortium-secures-eur14-9-million-eu-grant-to-advance-ai-powered-precision-cancer-treatment 2026-02-03T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/c7775858f984adf0/biosion-initiates-phase-1-trial-of-bsi-082-anti-sirpa-antibody-for-advanced-solid-tumors 2026-02-03T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/2822277993c7dd8e/expres2ion-biotech-reports-promising-immune-response-data-from-her2-targeting-cancer-vaccine-phase-i-trial 2026-02-03T13:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/f2c0b258b775372d/hemostod-secures-chf-2-million-innosuisse-grant-to-advance-universal-donor-free-platelet-technology 2026-02-03T13:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/8f32feb1fb33174c/meta-analysis-confirms-metastasis-directed-therapy-benefits-for-oligometastatic-prostate-cancer 2026-02-03T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/3be488bbb45ba98e/cdsco-plans-1500-member-scientific-cadre-to-accelerate-drug-approvals-and-meet-global-standards 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b7bb27444fb85f2/wuxi-biologics-partners-with-vertex-on-trispecific-t-cell-engager-for-autoimmune-diseases 2026-02-03T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/fbc3190decf884c2/fda-rejects-astrazeneca-s-subcutaneous-lupus-drug-saphnelo-despite-eu-approval 2026-02-03T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/f3894311ef2fed9f/pharming-advances-rare-disease-pipeline-with-napazimone-for-mitochondrial-disease-and-leniolisib-expansion 2026-02-03T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/fac7cec15afe92e3/large-swedish-study-finds-no-link-between-covid-19-vaccines-and-reduced-fertility 2026-02-03T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/5f56d60376cba344/persica-pharmaceuticals-pp353-shows-promising-results-for-chronic-low-back-pain-in-phase-1b-trial-published-in-the-lancet 2026-02-03T09:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/93cec61471507d82/nmd-pharma-s-ignaseclant-shows-promise-in-phase-2a-trial-for-charcot-marie-tooth-disease 2026-02-03T09:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/4942bb789828df03/vtv-therapeutics-expands-global-partnership-with-newsoara-for-pde4-inhibitor-hpp737-in-135-million-deal 2026-02-03T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/de6d341dfef87079/sglt2-inhibitors-reduce-gout-medication-burden-in-patients-with-type-2-diabetes 2026-02-03T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/eb940ad044dc8471/salspera-files-ipo-to-fund-phase-3-trial-of-saltikva-bacterial-immunotherapy-for-pancreatic-cancer 2026-02-03T01:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/e1f0958485a54bf1/imagion-biosystems-files-ind-application-for-magsense-targeted-imaging-agent-in-her2-positive-breast-cancer 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/659b5d2efdd9e095/ai-supported-mammography-screening-demonstrates-superior-cancer-detection-in-large-swedish-trial 2026-02-03T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/34e9681f72894669/avalo-therapeutics-completes-enrollment-in-phase-2-lotus-trial-for-hidradenitis-suppurativa-treatment 2026-02-03T01:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/a82ef97b7f112fbd/health-canada-proposes-ministerial-reliance-order-to-accelerate-drug-approvals-through-foreign-regulatory-collaboration 2026-02-03T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/f90e24bc860f10cc/zeiss-secures-nmpa-approval-for-advanced-ophthalmic-microscopes-in-china 2026-02-03T01:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/0a1e209e1e83852f/novel-stroke-rehabilitation-approach-targeting-good-arm-shows-significant-motor-improvements-in-phase-ii-trial 2026-02-03T01:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/93b738311d2319c6/ontario-approves-reimbursement-for-fruzaqla-in-metastatic-colorectal-cancer-treatment 2026-02-02T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/58500345b464f693/australia-launches-world-first-personalized-mrna-vaccine-trial-for-pediatric-brain-cancer 2026-02-02T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/13b00b2dc91a2e12/piramal-pharma-solutions-launches-tablet-in-capsule-technology-for-enhanced-drug-delivery 2026-02-02T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/8cd1e57c602e52c8/quotient-therapeutics-names-susan-keefe-as-cfo-to-advance-somatic-genomics-platform 2026-02-02T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/d264ff9e01b244f2/sanegenebio-secures-1-7-billion-rnai-licensing-deal-with-genentech 2026-02-02T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/b3acaf8ef83ad9b9/ensem-therapeutics-expands-etx-636-trial-to-china-targeting-pi3ka-mutations-in-cancer 2026-02-02T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/f19c2c21cc8d308c/neurothera-secures-u-s-patent-for-cannabinoid-enhanced-antimicrobial-platform-targeting-mrsa-and-antibiotic-resistance 2026-02-02T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/df503beaf13a6fea/thiogenesis-therapeutics-launches-investigator-initiated-study-for-once-daily-cystinosis-treatment 2026-02-02T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/b71f44c4650018f1/teva-canada-partners-with-novartis-to-commercialize-multiple-sclerosis-treatment-mayzent 2026-02-02T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/8c448b9de31c0957/sandoz-canada-launches-first-ophthalmology-biosimilar-enzeevu-for-retinal-diseases 2026-02-02T17:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/4a42be47644be41b/acurx-pharmaceuticals-secures-new-patent-for-dna-polymerase-iiic-inhibitors-targeting-antibiotic-resistant-bacteria 2026-02-02T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/6d017e605c9d7638/oxybutynin-demonstrates-significant-efficacy-in-reducing-hot-flashes-for-prostate-cancer-patients-on-hormone-therapy 2026-02-02T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/afd93089c98e7226/crystalys-therapeutics-expands-phase-3-ruby-study-to-europe-for-gout-treatment-dotinurad 2026-02-02T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/91cca56a466e6195/erleada-shows-51-reduction-in-death-risk-versus-darolutamide-in-real-world-prostate-cancer-study 2026-02-02T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/cd931ee402c6e63c/en-carta-diagnostics-receives-fda-breakthrough-device-designation-for-revolutionary-lyme-disease-test 2026-02-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/00c49bbdff1e007c/bioxytran-partners-with-university-of-minnesota-to-advance-carbohydrate-based-therapeutics-through-nmr-research 2026-02-02T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/eeaf5eeb58eee491/jumo-health-launches-prism-system-to-address-clinical-trial-patient-readiness-and-retention-challenges 2026-02-02T17:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/be66023f066e838d/oragenics-advances-toward-phase-2a-trial-for-first-in-class-concussion-treatment-onp-002 2026-02-02T17:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/63bb7c21a5582d09/gsk-returns-rna-editing-drug-wve-006-to-wave-life-sciences-following-disappointing-aatd-trial-data 2026-02-02T17:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/a3725f00f64243be/biorce-raises-52-5-million-series-a-to-transform-clinical-trials-with-ai-platform 2026-02-02T17:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/eec027fc67f7f7bc/southern-research-partners-with-pathogenus-to-expand-global-reach-in-respiratory-disease-and-cancer-research 2026-02-02T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/21639f4f6245be2b/alvotech-partners-with-sandoz-to-expand-biosimilar-access-across-canada-australia-and-new-zealand 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/d158a998c199fbfc/gameto-licenses-harvard-meiosis-technology-to-advance-human-ovary-in-a-dish-platform-for-women-s-health 2026-02-02T13:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/660e02679f30cc35/kahimmune-therapeutics-secures-exclusive-license-for-dark-genome-cancer-vaccine-platform 2026-02-02T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/8cf0bfae7562c1ef/india-s-supreme-court-to-determine-competition-commission-s-authority-over-patent-related-antitrust-cases 2026-02-02T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/d687eb1f16a52ff3/arctic-vision-acquires-mdco-technology-s-ophthalmic-device-business-to-create-integrated-drug-device-platform 2026-02-02T05:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/d356f63709b01fbe/nice-withdraws-car-t-therapy-tecartus-from-nhs-despite-patient-advocacy-appeals 2026-02-02T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/7d68a8744f50fb1f/international-consortium-develops-revolutionary-platform-to-predict-human-antibody-drug-responses 2026-02-02T05:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/ad5279943ddcb23a/texas-cardiac-arrhythmia-institute-performs-first-u-s-implantation-of-fda-approved-miniaturized-defibrillation-lead 2026-02-02T05:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/6eeca84cb5359218/novel-non-insti-hiv-treatment-shows-promise-in-phase-3-trial-amid-rising-resistance-concerns 2026-02-02T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/230904d54e0312e6/reata-pharmaceuticals-shifts-focus-to-omaveloxolone-commercialization-following-friedreich-s-ataxia-approval 2026-02-02T01:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/102c823645f78677/scot-trial-confirms-3-month-adjuvant-chemotherapy-noninferior-to-6-month-standard-for-colorectal-cancer 2026-02-02T01:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/6d6e3c407c112906/gsk-and-hansoh-pharma-advance-next-generation-her2-targeted-adc-gsk5764227-in-early-clinical-trials 2026-02-01T21:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/c45da8eda3fc3c3c/india-announces-rs-10000-crore-biopharma-shakti-initiative-and-cdsco-regulatory-overhaul-in-union-budget-2026 2026-02-01T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/8240834ef7da39f4/india-launches-rs-10000-crore-biopharma-shakti-initiative-and-exempts-17-cancer-drugs-from-import-duties 2026-02-01T09:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/634f891a4331c938/tenacia-biopharmaceuticals-partners-with-golden-age-health-to-launch-first-cdkl5-deficiency-disorder-treatment-in-china 2026-02-01T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/4f880e41a81885b6/supreme-court-bans-stem-cell-therapy-for-autism-outside-clinical-trials-declares-practice-medical-malpractice 2026-02-01T09:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/716c2c2e13ae931f/olema-pharmaceuticals-faces-leadership-transition-as-pivotal-breast-cancer-trial-data-approaches 2026-02-01T09:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/490db536025f088f/trace-biosciences-receives-fda-ind-clearance-for-first-in-class-nerve-specific-imaging-agent-lgw16-03 2026-02-01T09:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/250b8f0b82b3f245/cbd-shows-promise-in-reducing-fetal-alcohol-spectrum-disorder-effects-through-endocannabinoid-system-modulation 2026-02-01T00:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/19196a277e061d9d/gsk-completes-long-term-real-world-study-of-nucala-in-rare-eosinophilic-disease-egpa 2026-02-01T00:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/a4f75937b2422aa6/ardena-completes-divestment-of-swedish-api-manufacturing-site-to-nanologica 2026-01-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/980f37ad4504c676/brazilian-lawmakers-propose-patent-break-for-eli-lilly-s-mounjaro-as-ozempic-patent-expires 2026-01-31T13:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/f1763f7b4a7ad280/nasal-spray-h5n1-vaccine-shows-near-complete-protection-in-early-animal-studies 2026-01-31T05:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/803a704c7b43b8cd/indoco-remedies-secures-fda-approval-for-generic-lacosamide-oral-solution-for-epilepsy-treatment 2026-01-31T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/bc06865966cba5bb/vivosim-labs-expands-human-based-toxicology-services-to-asia-pacific-through-strategic-distribution-partnerships 2026-01-31T01:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/1a12ef2fae429f4d/major-pharmaceutical-patent-litigation-wave-intensifies-in-q4-2025-as-generic-manufacturers-challenge-key-drug-patents 2026-01-31T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/490b64deae95b45c/eli-lilly-builds-1-5-billion-pre-launch-inventory-for-oral-glp-1-obesity-drug-ahead-of-fda-decision 2026-01-30T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/5b1fa632e04537f3/illumina-completes-350-million-acquisition-of-somalogic-to-expand-proteomics-leadership 2026-01-30T21:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/ae92f285f179a97a/kyowa-kirin-regains-control-of-rocatinlimab-development-following-amgen-partnership-termination 2026-01-30T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/338cd482311877f7/moderna-cmo-jacqueline-miller-steps-down-as-company-seeks-to-expand-beyond-covid-vaccines 2026-01-30T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/6870a2c3a275f35a/novartis-reports-positive-phase-iii-results-for-fabhalta-in-rare-kidney-disease-c3-glomerulopathy 2026-01-30T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/99e1ac30d9cb1d4f/ipsen-partners-with-origami-therapeutics-on-protein-degrader-program-for-rare-neurodegenerative-diseases 2026-01-30T21:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/797207ec38bef751/kos-biotechnology-partners-makes-inaugural-investment-in-epikast-s-technology-enabled-pharma-services-platform 2026-01-30T21:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/8a575174b5bf5907/immunocore-restructures-r-d-leadership-as-executive-vp-berman-departs 2026-01-30T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/2af0ea5e47fd9a3b/kazia-therapeutics-unveils-first-in-class-nuclear-pd-l1-degrader-ndl2-targeting-immunotherapy-resistance 2026-01-30T17:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/211a9477168c53c6/neonc-technologies-secures-16-million-pipe-investment-to-advance-cns-cancer-therapies 2026-01-30T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/d5bf2c4f89845659/european-regulators-recommend-approval-of-needle-free-nasal-epinephrine-spray-for-pediatric-anaphylaxis 2026-01-30T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/5dbf5bf2478e8c1d/ema-initiates-data-integrity-review-of-amgen-s-tavneos-following-concerns-over-pivotal-advocate-study 2026-01-30T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/34b5d8106c607caf/metformin-emerges-as-first-proven-intervention-to-prevent-long-covid-in-adults 2026-01-30T13:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/318332bae9120968/brain-swelling-from-alzheimer-s-drugs-may-signal-treatment-success-new-research-suggests 2026-01-30T13:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/f64ff5d6c6cf66fb/poxel-emerges-from-judicial-reorganization-with-court-approved-recovery-plan 2026-01-30T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/243fae66dd374289/fda-approved-frostbite-drug-iloprost-shows-zero-amputation-rate-in-clinical-use-at-ohio-hospitals 2026-01-30T09:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/40e63c0138896849/sciwind-biosciences-receives-chinese-approval-for-glp-1-diabetes-drug-xianyida 2026-01-30T09:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/5364d9c3b113bd42/percheron-therapeutics-advances-hmbd-002-to-phase-ii-following-positive-safety-data-in-cancer-trial 2026-01-30T05:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/0ccc1a0c26ddcc2b/breakthrough-bioelectronic-patch-enables-precision-drug-delivery-to-complex-organs 2026-01-30T05:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/6e73feed6e2fd66d/biopharma-hiring-rebounds-as-companies-embrace-remote-work-and-ai-skills 2026-01-30T03:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/4b9beab6d58b9fe8/lexicon-pharmaceuticals-raises-94-6-million-to-advance-drug-pipeline-in-neuropathic-pain-and-hypertrophic-cardiomyopathy 2026-01-30T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/285e70be70797397/metp-pharma-s-nose-to-brain-technology-achieves-superior-peptide-delivery-compared-to-blood-brain-barrier-shuttles 2026-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/95dc759815b2606e/biotech-m-a-surge-expected-as-200-billion-patent-cliff-drives-big-pharma-acquisition-strategy 2026-01-30T01:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/6c9f42c0c9957b8b/tucatinib-combination-therapy-shows-remarkable-success-in-metastatic-esophageal-cancer-patient 2026-01-30T01:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/6e69c0bf79be74be/novel-bite-immunotherapy-reduces-arterial-plaque-in-preclinical-atherosclerosis-study 2026-01-29T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/9a7c7bb0ec8ce2e6/researchers-develop-bead-free-microfluidics-method-to-streamline-car-t-cell-manufacturing 2026-01-29T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/f9bd8a5286f2b3be/geneva-team-wins-pfizer-prize-for-personalized-cancer-vaccine-mvx-onco-1-showing-clinical-benefit-in-advanced-tumors 2026-01-29T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/143458a1dec9769e/eli-lilly-partners-with-repertoire-immune-medicines-in-1-93-billion-autoimmune-disease-deal 2026-01-29T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/6634b24399b40629/nucleic-acid-therapeutics-contract-manufacturing-market-surges-to-33-84-billion-by-2033 2026-01-29T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/0fac2e3703726d7b/breakthru-medicine-emerges-from-stealth-with-60m-series-a-to-develop-novel-cancer-therapeutics 2026-01-29T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/3614182557f22656/pulmonary-arterial-hypertension-pipeline-expands-with-55-therapies-as-merck-s-winrevair-shows-76-mortality-risk-reduction 2026-01-29T17:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/39f80bf998aaa1bc/micurx-receives-fda-clearance-to-advance-mrx-5-into-phase-2a-trial-for-mycobacterium-abscessus-pulmonary-disease 2026-01-29T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/848d53074c95aa3b/heidelberg-pharma-receives-milestone-payment-from-takeda-as-atac-based-adc-enters-phase-i-ii-trial 2026-01-29T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/9ca8861b2c053095/bioxytran-advances-multi-platform-pipeline-with-prolectin-m-under-fda-ind-and-oxygen-transport-programs 2026-01-29T17:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/4effc044142bdcf8/insilico-medicine-s-ai-designed-gipr-antagonist-ism0676-achieves-31-3-weight-loss-in-preclinical-studies 2026-01-29T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/dc94b6c1db20e380/long-term-jcog0603-trial-results-show-no-overall-survival-benefit-from-adjuvant-mfolfox6-after-liver-resection-for-colorectal-metastases 2026-01-29T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/a6790e0f3f83efcf/dod-awards-genomind-contract-to-implement-pharmacogenomics-testing-for-active-duty-service-members 2026-01-29T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/59c5cbb1f3ef778e/panakeia-s-ai-software-achieves-landmark-validation-for-rapid-colorectal-cancer-molecular-profiling 2026-01-29T17:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/987449500e7c4146/large-scale-meta-analysis-finds-no-significant-vision-risk-from-glp-1-receptor-agonists-in-80000-patients 2026-01-29T17:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/ba5a426228dbb638/aprea-therapeutics-reports-second-partial-response-for-wee1-inhibitor-apr-1051-in-phase-1-endometrial-cancer-trial 2026-01-29T13:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/c00d839b890c9c5e/aicuris-pritelivir-demonstrates-superior-efficacy-in-phase-3-trial-for-drug-resistant-hsv-infections 2026-01-29T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/067113c1ad5b0d6e/pre-surgical-pembrolizumab-achieves-71-complete-response-rate-in-desmoplastic-melanoma-trial 2026-01-29T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/a8c5d48dd40f6af4/darolutamide-receives-third-approval-in-china-for-metastatic-hormone-sensitive-prostate-cancer 2026-01-29T13:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/fb5af6db56086f0c/china-approves-seysara-for-moderate-to-severe-acne-treatment-in-patients-9-years-and-older 2026-01-29T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/3c415c612f8f91cb/ena-respiratory-initiates-phase-ii-trial-of-inna-051-nasal-spray-for-viral-respiratory-infection-prevention 2026-01-29T13:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/9086c4fce3001586/oncoinvent-expands-phase-2-trial-sites-for-radspherin-radiopharmaceutical-in-ovarian-cancer 2026-01-29T13:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/e00a74be42673873/fda-qualifies-moleculightdx-as-medical-device-development-tool-for-wound-care-innovation 2026-01-29T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/93ae072214efb7ca/enterome-strengthens-board-with-beigene-s-former-cmo-as-oncomimics-platform-shows-promise-in-cancer-trials 2026-01-29T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/e6b41e405db43a2a/eyestem-receives-cdsco-approval-for-phase-2-trial-of-stem-cell-therapy-for-dry-amd 2026-01-29T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/abf63792830db0db/serina-therapeutics-receives-fda-ind-clearance-for-ser-252-parkinson-s-disease-therapy 2026-01-29T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/cc3fa8aba87b5833/qurebio-s-q-1802-bispecific-antibody-shows-70-response-rate-in-advanced-gastric-cancer-phase-ii-trial 2026-01-29T09:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/bc0d009f7db29181/avobis-bio-reports-positive-expanded-stomp2-trial-results-for-crohn-s-perianal-fistula-cell-therapy 2026-01-29T07:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/46af7347748a4b91/bexorg-receives-michael-j-fox-foundation-grant-to-develop-trpml1-biomarkers-for-parkinson-s-disease 2026-01-29T05:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/f12ad7adf8b2b16c/mabtech-and-sai-life-sciences-form-strategic-partnership-to-expand-eyra-immunology-platform-access-in-us-market 2026-01-29T05:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/a68f40547534cdef/sk-bioscience-launches-first-in-class-universal-coronavirus-vaccine-trial-targeting-entire-sarbecovirus-family 2026-01-29T05:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/44566dc278c07ed2/paradigm-biopharmaceuticals-advances-osteoarthritis-program-with-peer-reviewed-validation-of-injectable-pps 2026-01-29T05:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/f697ea88b309371b/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia-treatment 2026-01-29T05:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/25853ea1d1a8175f/dr-reddy-s-files-first-orencia-biosimilar-application-with-fda-targeting-2-77-billion-market 2026-01-29T01:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/d9f5a7fb0e98149c/eric-schmidt-backed-ai-biotech-hologen-seeks-150-million-to-de-risk-clinical-trials 2026-01-28T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/6c7296891c4cafb5/calcimedica-halts-phase-ii-kidney-injury-trial-following-safety-concerns-stock-plummets-75 2026-01-28T21:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/3d00fb9a3344e47a/enzian-pharmaceutics-expandable-fibrous-dosage-form-triples-bioavailability-of-sparingly-soluble-drugs 2026-01-28T21:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/e435f77fc5c8ba07/pacira-biosciences-strengthens-board-with-former-bristol-myers-squibb-cmo-samit-hirawat 2026-01-28T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/b5f4f35f127de3b1/unravel-biosciences-partners-with-scn2a-foundation-to-target-loss-of-function-mutations-in-autism-and-epilepsy 2026-01-28T21:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/3f7aeded92b907ba/siren-biotechnology-receives-fda-clearance-for-first-aav-based-cancer-gene-therapy-ind 2026-01-28T21:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/57e311b4bb0e5c47/solriamfetol-shows-promise-for-treating-excessive-sleepiness-in-early-morning-shift-workers 2026-01-28T21:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/aa8c50f4e95d81d5/halo-pharma-emerges-as-independent-cdmo-following-noramco-group-divestiture-to-siegfried 2026-01-28T17:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/fa4b031be5aabaa7/health-canada-accepts-cipher-pharmaceuticals-new-drug-submission-for-natroba-spinosad-to-treat-head-lice-and-scabies 2026-01-28T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/08be102a4f852026/ardelyx-initiates-phase-3-accel-trial-for-ibsrela-in-chronic-idiopathic-constipation 2026-01-28T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/85bbd79994de9bcc/sensorion-secures-eur60m-funding-round-led-by-sanofi-to-advance-gene-therapy-pipeline-for-hearing-loss 2026-01-28T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/b16cf0994e6da886/eliquis-faces-major-patent-cliff-as-european-exclusivity-expires-in-may-2026 2026-01-28T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/d20cd15d40e6efa9/life-biosciences-receives-fda-clearance-for-first-ever-cellular-rejuvenation-therapy-using-epigenetic-reprogramming 2026-01-28T17:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/39ced1fe9b71a9e9/eli-lilly-partners-with-seamless-therapeutics-in-1-1-billion-gene-editing-deal-for-hearing-loss 2026-01-28T17:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/f348fcdb2a29bd04/nine-marker-molecular-signature-identified-as-driver-of-lapatinib-resistance-in-her2-positive-breast-cancer 2026-01-28T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/959e9300f96f0a89/onkure-faces-critical-data-readout-for-h1047r-specific-pi3ka-inhibitor-as-competition-intensifies 2026-01-28T17:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/79eb49045b4f73b2/world-first-brain-targeting-exosome-platform-delivers-curcumin-across-blood-brain-barrier-for-parkinson-s-disease 2026-01-28T17:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/70aa15944aaa3db6/fda-approves-larger-vial-size-of-nelarabine-injection-for-t-cell-leukemia-and-lymphoma-treatment 2026-01-28T17:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/46cc12ef8cf4335c/fecal-microbiota-transplant-capsules-show-breakthrough-results-in-cancer-immunotherapy-trials 2026-01-28T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/97d9cbdc3aa051da/insmed-to-present-tpip-data-at-pvri-2026-congress-including-phase-3-palm-pah-study-design 2026-01-28T17:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/1fe876cdb99865c7/60-degrees-pharmaceuticals-advances-castanospermine-development-with-florida-state-university-license 2026-01-28T17:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/e1e96ba6477b0eb3/fda-approves-repeat-administration-of-idose-tr-intracameral-implant-for-glaucoma-treatment 2026-01-28T17:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/569d2bd088950dcb/cannabis-based-medicines-show-mixed-results-for-fibromyalgia-pain-management 2026-01-28T13:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/af23d77a38d13ed1/alnylam-pharmaceuticals-prepares-for-q4-results-with-amvuttra-sales-surge-and-pipeline-advances 2026-01-28T13:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/d1bc074c15b614c9/fecal-microbiota-transplantation-shows-promise-in-enhancing-cancer-immunotherapy-across-multiple-tumor-types 2026-01-28T13:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/912d59f79e344b65/life-biosciences-secures-first-fda-approval-for-human-epigenetic-reprogramming-trial-to-reverse-vision-loss 2026-01-28T13:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/5496196da8d52ee6/altido-therapeutics-raises-12-5m-to-advance-car-t-therapy-for-glioblastoma 2026-01-28T13:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/d8d05546d06d6298/four-biomarker-blood-panel-shows-promise-for-early-pancreatic-cancer-detection 2026-01-28T09:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/24d41eb26c513ef0/fujirebio-launches-automated-ptau-217-csf-assay-for-alzheimer-s-disease-research 2026-01-28T09:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/f9f15ff3d4bb2fa4/boehringer-ingelheim-s-apecotrep-shows-40-proteinuria-reduction-in-phase-ii-trial-for-rare-kidney-disease-fsgs 2026-01-28T09:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/a4e63a52bdccff86/first-topical-crispr-gene-therapy-successfully-corrects-disease-causing-mutations-in-human-skin 2026-01-28T05:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/93262ba0679db4d0/leading-cancer-researchers-unite-to-accelerate-therapeutic-cancer-vaccine-development 2026-01-28T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/d6fe279091f61a9c/icotrokinra-demonstrates-superior-efficacy-over-oral-therapies-in-psoriasis-meta-analysis 2026-01-28T05:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/5cb733286ba04ca4/cranius-therapeutics-secures-20m-series-b-to-advance-blood-brain-barrier-bypass-platform 2026-01-28T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae1f16401e19d554/genyro-secures-exclusive-license-for-sidewinder-dna-construction-technology-with-one-in-million-error-rate 2026-01-28T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/b8161d1148cd1841/federal-circuit-clarifies-patent-eligibility-standards-for-machine-learning-technologies-in-healthcare-innovation 2026-01-28T01:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/1e801b221ea13804/swiftstart-announces-80-million-strategic-investment-intent-in-tirx-at-1-50-per-share 2026-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a61501a9f96227f/kalaris-therapeutics-to-present-first-in-human-data-for-novel-dual-targeting-amd-therapy-th103 2026-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/307f8a86ac2131e7/outset-medical-s-next-generation-tablo-hemodialysis-system-receives-fda-clearance-with-enhanced-cybersecurity 2026-01-27T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/6c77802c47cd45af/myra-vision-initiates-first-in-us-trial-of-adjustable-glaucoma-shunt-system 2026-01-27T21:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/0b34d0d490c23b55/starkage-therapeutics-partners-with-gustave-roussy-to-advance-first-in-class-senolytic-adc-for-digestive-cancers 2026-01-27T21:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/5701993e45b786ac/northwell-health-opens-psychedelics-research-center-to-advance-mental-health-treatments 2026-01-27T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/cc4775d548d0f2ec/drug-farm-s-df-003-receives-fda-fast-track-designation-for-rosah-syndrome-treatment 2026-01-27T21:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/2a7f81201b4076a6/uva-scientists-develop-revolutionary-vaccine-platform-promising-3-week-development-timeline 2026-01-27T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/739bd11f8ed89948/hyaluronidase-co-administration-enhances-cancer-immunotherapy-efficacy-through-subcutaneous-delivery 2026-01-27T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/8db420962930d7b1/ixcells-biotechnologies-and-rosebud-biosciences-form-strategic-partnership-to-advance-3d-organoid-models-for-rare-disease-drug-development 2026-01-27T17:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/e6cffab7e1833412/vyome-seeks-orphan-drug-status-for-vt-1953-as-independent-analysis-values-asset-at-1-billion-post-phase-3 2026-01-27T17:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/ea6ce8aafc676baa/trexbio-secures-50m-to-advance-novel-regulatory-t-cell-therapy-for-atopic-dermatitis 2026-01-27T17:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/1950435eb027a10d/tempus-ai-s-ips-test-outperforms-standard-biomarkers-in-predicting-immunotherapy-response 2026-01-27T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/e1d5cb5270e5bf1c/abli-therapeutics-partners-with-michael-j-fox-foundation-to-test-risvodetinib-in-parkinson-s-prevention-trial 2026-01-27T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/9d04d1e68d439a33/opus-genetics-launches-first-mertk-gene-therapy-clinical-trial-for-rare-inherited-blindness 2026-01-27T17:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/b20db3184f4aa4ac/fda-lifts-clinical-hold-on-intellia-s-crispr-gene-therapy-for-rare-nerve-disease 2026-01-27T17:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/f67ba144223d54f7/bial-s-phase-2b-activate-study-reaches-75-completion-milestone-for-gba1-associated-parkinson-s-disease-treatment 2026-01-27T17:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/7b5a1bea18dab931/sglt2-inhibitors-prevent-age-related-kidney-deterioration-in-breakthrough-aging-model-study 2026-01-27T17:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/db5cbf909e04a4f6/boehringer-ingelberg-acquires-novel-dual-target-ibd-therapy-in-eur1-05-billion-deal-with-simcere 2026-01-27T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/048643675a657d12/skyhawk-therapeutics-reports-promising-nine-month-data-for-huntington-s-disease-drug-sky-0515 2026-01-27T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/0c865bd38e798abe/rakovina-therapeutics-secures-1-5-million-financing-and-appoints-new-ceo-to-advance-cancer-drug-pipeline 2026-01-27T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/133b33765ea0c602/landmark-study-demonstrates-sleep-driven-clearance-of-alzheimer-s-proteins-in-human-brain 2026-01-27T13:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/ce44415b2e4be4ee/china-s-new-cell-and-gene-therapy-regulations-set-to-accelerate-clinical-development-starting-may-1 2026-01-27T13:57:05+00:00 hourly 0.9 https://trial.medpath.com/news/fb74cb41c34f4d7e/icr-develops-first-standardized-guidelines-for-patient-reported-outcomes-in-early-cancer-drug-trials 2026-01-27T13:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/a44e36d8282b90bc/prospera-test-reduces-need-for-invasive-lung-transplant-biopsies-by-75-in-ohio-state-study 2026-01-27T13:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/a2a4a7e8d3f6c7aa/skyx-technologies-secures-25-million-funding-and-expands-smart-home-platform-with-nvidia-collaboration 2026-01-27T13:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/ab462f489ab98d16/roche-s-experimental-obesity-drug-ct-388-achieves-22-5-weight-loss-in-phase-ii-trial 2026-01-27T09:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/d06859fc558193e8/qilu-pharmaceutical-partners-with-insilico-medicine-in-120-million-ai-driven-metabolic-disease-drug-development-deal 2026-01-27T09:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/b4abe257c61f48c4/china-s-nmpa-accepts-review-of-ohtuvayre-for-copd-maintenance-treatment 2026-01-27T09:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/044dc28adb5b6750/avant-technologies-advances-cell-in-a-box-technology-for-immunosuppression-free-diabetes-therapy-at-epita-symposium 2026-01-27T03:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/0fadd5e3420801d8/ret-fusion-targeted-therapies-market-projected-for-significant-growth-through-2034 2026-01-27T03:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/3ab4c710c4c982f9/gri-bio-secures-patent-protection-for-novel-nkt-cell-targeting-compounds-across-inflammatory-diseases 2026-01-27T03:43:58+00:00 hourly 0.9 https://trial.medpath.com/news/ec8d3be36bd51cb1/scancell-receives-fda-clearance-for-phase-3-trial-of-iscib1-immunobody-in-advanced-melanoma 2026-01-27T03:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/af400beb71e7bde2/alphamab-advances-first-pd-l1-x-vegfr2-antibody-drug-conjugate-jskn027-into-clinical-trials 2026-01-27T03:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf100df7e9e50abb/keros-therapeutics-advances-ker-065-for-duchenne-muscular-dystrophy-following-fda-orphan-drug-designation 2026-01-27T03:39:17+00:00 hourly 0.9 https://trial.medpath.com/news/81462d02d3dbdb5b/fortitude-biomedicines-launches-with-13m-seed-funding-to-advance-novel-glue-dac-platform-for-cancer-and-autoimmune-diseases 2026-01-27T03:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/7a1756ca09eb72da/fda-provides-development-pathway-for-novel-women-s-testosterone-therapy-with-reduced-breast-cancer-risk 2026-01-27T03:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/c4c638ac058cc76b/city-of-hope-launches-phase-2-trial-testing-heart-protection-strategies-for-prostate-cancer-patients-on-hormone-therapy 2026-01-27T03:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/cf40cae3daf22120/pila-pharma-advances-to-clinical-obesity-trials-despite-inconclusive-preclinical-results 2026-01-27T03:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/bbfcd2450cb3be80/fda-clears-first-at-home-4-in-1-respiratory-test-for-infants-and-adults 2026-01-27T03:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/21c336bcb092834d/primmune-therapeutics-raises-8-6m-to-advance-tlr7-agonist-prtx007-into-phase-2-melanoma-trial 2026-01-27T03:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/a4de28ee83cff89b/gene-therapy-targeting-connexin-43-shows-promise-for-treating-inherited-heart-disease-in-young-athletes 2026-01-27T03:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/130bd3f34524e799/focus-graphite-secures-canadian-patent-for-silicon-enhanced-graphite-anode-technology 2026-01-27T03:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/95f24ba6c175b349/novaliq-receives-fda-ind-clearance-for-nov05-phase-ii-trial-in-non-infectious-anterior-uveitis 2026-01-27T03:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/a6a85391bc906b79/cabozantinib-temozolomide-combination-shows-promise-in-advanced-leiomyosarcoma-with-74-disease-control-rate 2026-01-27T03:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/dd5ec0b0a8173cbd/lb-pharmaceuticals-launches-phase-2-trial-of-lb-102-for-bipolar-depression-following-positive-schizophrenia-results 2026-01-27T03:30:45+00:00 hourly 0.9 https://trial.medpath.com/news/b32dcd44e3301d61/mair-therapeutics-partners-with-radboud-university-to-advance-novel-tmem175-agonists-for-parkinson-s-disease 2026-01-27T03:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/7492a750f49168c3/leios-therapeutics-partners-with-bnc-korea-for-10xb-101-fat-reduction-treatment-development 2026-01-27T03:30:14+00:00 hourly 0.9 https://trial.medpath.com/news/f744d71730a58019/fda-clears-expanded-access-program-for-stemcyte-s-cord-blood-therapy-following-successful-long-covid-trial 2026-01-27T03:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/1aaff03a4d78d1c7/bausch-health-s-xifaxan-successor-fails-phase-iii-trials-for-hepatic-encephalopathy-prevention 2026-01-27T03:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/6d70ae7a50bf1b7f/united-therapeutics-reports-positive-phase-1-results-for-world-s-first-bioengineered-liver-device-in-acute-liver-failure 2026-01-27T03:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/e04030de35f41310/takeda-launches-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-in-u-s 2026-01-27T03:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/008a7c417b4a7f54/merz-therapeutics-seeks-european-approval-for-xeomin-in-pediatric-spasticity-treatment 2026-01-27T03:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/59de5f1cc08d0cee/cxcr4-engineering-transforms-car-t-cell-therapy-enhanced-memory-formation-and-durable-anti-leukemic-immunity 2026-01-27T03:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/1a76111a8a76cc55/world-s-first-gene-therapy-during-heart-bypass-surgery-targets-vessel-longevity-in-scotland 2026-01-27T03:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/7342febde1d629b9/real-world-analysis-reveals-stark-survival-differences-in-multiple-myeloma-treatment-across-england 2026-01-27T03:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/f563693605e4e862/moyom-biotechnology-partners-with-wpp-group-to-advance-aphranel-s-global-brand-strategy-in-regenerative-aesthetics 2026-01-27T03:22:42+00:00 hourly 0.9